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CHAPTER 1: INTRODUCTION 
1.1 Oral Microbiology Background 
The oral microbiome is quite complex; from the extreme numbers of oral microbiota that 
colonize the oral cavity, to the different combinations of groups of oral microbiota that colonize 
specific areas and surfaces of the oral cavity. The NIH Human Microbiome Project (HMP) has 
recently revealed that the oral microbiome, as compared to the gut or skin, has the largest core of 
commonly shared microbes among unrelated individuals 1, 2. More specific to the oral 
microbiome than the HMP, the Human Oral Microbiome Database (HOMD) (www.homd.org) 
was developed using a provisional taxonomic scheme for unmatched oral bacterial isolates and 
phylotypes. A total of 36,043 16s rRNA gene oral clone sequences were analyzed to identify 
additional taxa not included in the initial set up of the HOMD. The HOMD consists of 619 Oral 
taxa with 6 major phyla (Firmicultes, Bacteroidetes, Proteobacteria, Actinobacteria, 
Spirochaetes, and Fusobacteria) that make up 96% of the taxa among all oral bacteria 3.  
There are many different groups of microbiota that dominate depending on their location 
in the oral cavity, such as the hard palate, saliva, subgingival plaque or throat. These groups can 
be found in Table 1 below. For instance, in the healthy oral cavity, saliva contained the major 
core genera of Prevotella, Streptococcus, Veillonella, Pasteurellaceae, Fusobacterium, 
Porphyromonas, Neisseria, and unclassified bacteria (Uncl) 2. The most abundant that dominated 
nearly all oral mucosal sites was Streptococcus: Streptococcus oralis, Streptococcus mitis, and 
Streptococcus peroris 4. 
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Table 1. The core bacterial taxa in the oral cavity from over 200 healthy individuals participating in 
HMP 
Sample type 
High abundance core 
genera in >75% 
samples at >10% 
abundance 
Other major core genera in >80% 
samples at >1% abundance 
Minor core genera in 
>50% samples 
Buccal 
mucosa 
Streptococcus (2) 
Uncl. Pasteurellaceae (16, 19), Gemella 
(11) 
Atopobium, Uncl. 
Prevotellaceae, Uncl. 
Bacilli, Catonella 
Hard palate Streptococcus (2, 6) 
Uncl. Pasteurellaceae (16), Veillonella 
(4), Prevotella (10), Uncl. 
Lactobacillales (13), Gemella (11) 
Mogibacterium Catonella 
Keratinized 
gingiva 
Streptococcus (2), 
Uncl. Pasteurellaceae 
(19) 
  Uncl. Bacilli 
Palatine 
tonsils 
  
Streptococcus (2, 6), Veillonella (4), 
Prevotella (10), Fusobacterium (9), 
Uncl. Pasteurellaceae (16) 
Mogibacterium, Uncl. 
Firmicutes 
Saliva   
Prevotella (10), Streptococcus (2, 6), 
Veillonella (4), Uncl. Pasteurellaceae 
(16), Fusobacterium (9), Porphyromonas 
(7), Neisseria (−) 
Uncl. Actinomycetales, 
Tannerella, Kingella 
Subgingival 
plaque 
  
Streptococcus (2), Fusobacterium (9), 
Capnocytophaga (−), Prevotella (−), 
Corynebacterium (−), Uncl. 
Pasteurellaceae (−) 
Uncl. Firmicutes 
Supragingival 
plaque 
  
Streptococcus (2), Capnocytophaga (−), 
Corynebacterium (15), Uncl. 
Pasteurellaceae (−), Uncl. Neisseriaceae 
(21), Fusobacterium (9) 
Uncl. Betaproteobacteria 
Throat Streptococcus (2, 6) 
Veillonella (4), Prevotella (10), Uncl. 
Pasteurellaceae (16), Actinomyces (−), 
Fusobacterium (9), Uncl. 
Lachnospiraceae (−) 
Mogibacterium, Uncl. 
Firmicutes 
Tongue 
dorsum 
Streptococcus (2, 6) 
Veillonella (4), Prevotella (10), Uncl. 
Pasteurellaceae (16), Actinomyces (14), 
Fusobacterium (9), Uncl. Lactobacillales 
(13), Neisseria (8) 
Uncl. Actinomycetales, 
Uncl. Bacilli, 
Peptostreptococcus 
HMP 2, 4. In the parentheses is the corresponding operational taxonomic unites in the genus or family. 
Uncl is the abbreviation used for unclassified. 
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There are a large number of different species, both bacterial and fungal, found in the 
healthy. A study done by Kumar et al. in 2005 found that phylotypes significantly associated 
with healthy patients were: Veilonella, Campylobacter gracilis, Abiotrophia adiacens, 
Eubacterium saburreum, Capylobacter showae, Gemella, Streptococus sanguis, 
Capnocytophaga gingivalis, Streptococcus mutans, Abiotrophia, Rothia dentocariosa, 
Eubacterium, and Selenomonas 5. In healthy individuals, 5 genera of fungi have been found. 
They are consisted of Candida species, Cladosporium, Aureobasidium, Saccharomycetales, and 
Aspergillus 6. 
Many studies have shown that specific oral bacteria are associated with disease. The most 
prevalent worldwide chronic infectious disease, dental caries, has been found to have changes in 
the abundance of genera depending on the stage of the caries 7. Dental caries was previously 
thought to be associated with Streptococcus mutans, however, molecular analysis has shown that 
there is a predominance of Atopobium, Propionibacterium or Prevotella, with Streptococcus or 
Actinomyces in carious dental lesions 8. Other genera found to be associated with dental caries 
are Lactobacillus, Atopobium, Olsenella, Propionibacterium, Bifidobacterium, Dialister, 
Sphingomonas and Parascardovia 9. The “Red complex”, consisting of Porphyromonas 
gingivalis, Tannerella forsythensis (formerly Bacteroides forsythus), and Treponema denticola, 
have been found to be elevated in patients with chronic periodontitis 10 5. Aggregatibacter 
actinomycetemcomitans has also been found to be a periodontal pathogen 11. Whereas, 
Tannerella forsythia, Peptostreptococcus micros (Parvimonas micra), Fusobacterium nucleatum 
subsp., Haemophilus paraphrophilus and Capnocytophaga sp. have been found to be associated 
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with gingivitis 12. Taxa also found to be associated with gingivitis included Fusobacterium 
nucleatum subsp. polymorphum, Lachnospiraceae [G-2] sp. HOT100, Lautropia sp. HOTA94, 
and Prevotella oulorum, whilst Rothia dentocariosa was associated with periodontal health 13. 
Halitosis bacteria are Porphyromonas gingivalis, Fusobacterium nucleatum, Prevotella 
intermedia and Solobacterium moorei 14. Particular Candida species have been found to be 
involved in oral mucosal disorders in patients with xerostomia, such as Candida albicans, 
Candida glabrata, Canadida tropicalis, and Candida krusei 15.  
The analysis of the association of specific or groups of microbes with oral disease and 
health have been a great insight to causes and treatment. The methods of determining the 
microbiota include culture, PCR or qPCR after microbial DNA extraction, DGGE and Next 
Generation Sequencing 5, 16, 17. The continuation of further microbial associations with oral 
diseases and building of the HOMD through microbial DNA extraction, directly from saliva, and 
sequencing needs to be done, especially those that have not been done already, such as 
xerostomia. 
1.2 Xerostomia 
Approximately 5.5% to 46% of the population suffers from the burden of xerostomia 18.  
The prevalence and diagnosis of xerostomia and salivary gland hypofunction is very difficult to 
determine with certainty owing to the limited number of epidemiological studies and differences 
in how the two conditions have been defined. Xerostomia is the subjective feeling of dry mouth, 
a symptom that may or may not be accompanied by hyposalivation, an objective decrease in 
salivary flow. The stimulated salivary flow rate for healthy, non-hyposalivation averages 1.5–2.0 
5 
 
mL/min and the unstimulated salivary flow rate is approximately 0.3–0.4 mL/min 18, 19. For 
xerostomia, however, the individual has a stimulated flow rate below 0.5 mL/min, and an 
unstimulated flow rate below 0.12-0.16 mL/min 20. Chronic xerostomia has significant negative 
implications that may affect the comfort of the oral cavity, bad oral hygiene and general well-
being; salvia is very important for lubrication and oral health; negative oral health such as dental 
caries, oral fungal infections, halitosis, or burning mouth 19-21. The cause of xerostomia can be 
induced from both salivary and non-salivary reasons (such as mouth breathing, psychological 
disorders, and dehydration) 20. There are several types of treatments and ways to manage the 
negative side effects of the disease, however, further understanding at the microbial level may be 
helpful in understanding the disease as a whole and may be helpful in developing better 
treatments. 
1.2.1 Causes 
There are several possible causes for the development of xerostomia. The most frequent 
cause of hyposalivation is the use of certain medications, radiotherapy to the head and neck, and 
certain diseases. Other factors include salivary gland trauma or tumors, depression, anxiety and 
stress, mouth breathing, psychological disorders, or malnutrition 18, 20. Medications that have 
been associated with dry mouth are anticoagulants, antidepressants, anti-hypertensives, anti-
retrovirals, hypoglycemics, levothyroxine, non-steroidal anti-inflammatory drugs, and steroid 
inhalers 18. Diseases that have been thought to cause xerostomia are Sjögren’s syndrome, 
autoimmune disorders, diabetes mellitus, HIV, sarcoidosis, herpes virus, hepatitis C and end-
stage renal disease. Sjögren’s syndrome (SS), a chronic, autoimmune, inflammatory disorder 
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characterized by lymphocytic infiltration of the exocrine glands in multiple sites, most 
commonly the lacrimal and salivary glands. It can occur alone (primary SS), or in conjunction 
with another autoimmune rheumatic disease (secondary SS). Clinically, patients with SS most 
often present with a complaint of dry eyes (keratoconjunctivitis sicca) and dry mouth 20. 
1.2.2 Current Diagnosis Methods 
The diagnosis of xerostomia is done through by assaying the individuals reported 
symptoms, medication use, and past medical history. To help identify whether patients are 
experiencing xerostomia or hyposalivation, several dental health questionnaires have been 
proposed and used. These questionnaires ask questions about comfort of mouth, dryness of entire 
internal and external oral cavity, if there is any difficulty talking, swallowing or eating dry foods, 
and similar questions 18. Medications that may reduce saliva flow should be noted when 
identifying whether it could be a cause of the chronic xerostomia or hyposalivation. Finally, the 
medical history should be examined for any radiation treatment of the head and neck region, and 
other systemic diseases that have be found to induce xerostomia. In addition, an oral examination 
can be used to identify clinical signs pathognomonic for hyposalivation. These signs include: 
sticking of an intraoral mirror to the buccal mucosa or tongue, frothy saliva, no saliva pooling in 
floor of mouth, loss of papillae of the tongue dorsum, altered/smooth gingival architecture, 
glassy appearance to the oral mucosa (especially the palate), lobulated/deeply fissured tongue, 
cervical caries (more than two teeth); and/or mucosal debris on palate (except under dentures) 22. 
Another indication of xerostomia is found through a stimulated and unstimulated salivary flow 
tests. Most of the tests are easy to perform and require little time. As previously mentioned, 
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xerostomia patients tend to have a stimulated flow rate below 0.5 mL/min, and an unstimulated 
flow rate below 0.12-0.16 mL/min 20. More extreme xerostomia diagnosis measures include 
salivary imaging by ultrasonography or magnetic resonance imaging or salivary biopsy of the 
major or minor salivary glands 20. 
1.2.3 Current Treatment Methods 
There are several treatment strategies that can be used for the management of xerostomia. 
These strategies aim to reduce patients’ symptoms and/or increase salivary flow. Xerostomia 
symptoms can be managed by diet modifications, proper hydration, increase in humidity at 
night-time, avoidance of crunchy/hard foods and use of salivary substitutes and lubricants (such 
as rinses, gels, sprays, toothpastes, and artificial saliva) 20. Patients can increase salivary flow by 
using sugar-free, xylitol-containing mints, candies and gum, sialagogues (drugs that increase 
saliva flow) and acupuncture. Two systemic US Food and Drug Administration-approved 
sialagogues are pilocarpine and cevimeline 18. Following the bad oral hygiene that come from 
xerostomia, individuals may have to treat these oral conditions by the restoration of dental caries, 
antifungal medications to treat oral candidiasis, antibiotics for bacterial infections, and denture 
adjustments and or denture adhesives 20. However, there are some preventative measures that can 
be used to avoid some of the bad oral hygiene effects from xerostomia. By increasing the 
frequency of oral/dental evaluation by a dentist and use of topical fluoride applications the status 
of oral hygiene can be closely monitored and maintained 20. 
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1.2.4 Characterization of Xerostomia Microbiota 
There is a great understanding of the implications of xerostomia, but there are few studies 
that analyze the microbial environment by qPCR (quantitative polymerase chain reaction) or 
NGS (next-generation sequencing), while others were done by culturing followed with qPCR for 
identification. A recent culture study on xerostomia found total numbers of Candida albicans 
were significantly higher in patients with xerostomia (67%) than in the controls (13%) 23. 
Irradiated, dentate, xerostomia individuals’ oral rinses were cultured and Acinetobacter, 
Neisseria, Chryseomonas, Flavimonas, Pseudomonas, Citrobacter, Enterobacter, Escherichia, 
Klebsiella, Flavobacterium and Weeksella species were prevelent 24. Klebsiella pneumoniae 
subsp. pneumoniae was found to be significantly more prevalent in the irradiated subjects, and 
Enterobacteriaceae were found more frequently in aged irradiated subjects, where Citrobacter 
freundii was also significantly elevated in the culture based study 24. Another culture study with 
the addition of PCR identification showed mean levels of Streptococcus mutans, Lactobacilli 
spp. and Candida spp. to be significantly higher in medicated hypertensive xerostomia patients 
and primary Sjögren’s syndrome 17, 25.  
 Several studies that assay the microbial composition of dry mouth/hyposalivation. For 
instance, a culture study done on complete denture wearers, found that as the salivary flow rate 
(mL/5 min) decreased, it was found that the number of anaerobic bacteria and Candida species 
increased 1.4 x 109 CFU/mL 26. Patients with Sjögren’s syndrome contained significantly higher 
proportions of cultures of Streptococcus mutans, Candida albicans, Actinomyces naeslundii and 
Lactobacillus spp. (specifically L. acidophilus) 27. Head and neck radiotherapy patients’ saliva 
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was assayed by high-throughput sequencing, and 11 genera were found in all subjects: 
Streptococcus, Actinomyces, Veillonella, Capnocytophaga, Derxia, Neisseria, Rothia, 
Prevotella, Granulicatella, Luteococcus and Gemella 28.  
Further research needs to be done with PCR and Next Generation Sequencing on DNA of 
oral microbiota in xerostomia patients. Culture methods can be limiting in types of microbiota 
growth and methods of non-specific oral microbial DNA extraction combined with PCR and 
Next Generation Sequencing could be a better method for analysis. By getting a better, and full 
understanding of xerostomia at the microbial level could help with better diagnosis and treatment 
methods. 
1.3 Standard Oral Hygiene Practices 
Recent findings have found that douching is counterproductive in maintaining a healthy 
collection of vaginal microbes 29. With this idea in mind, are certain mouthwashes 
counterproductive in keeping the healthy groups of oral microbes? The primary use for 
antimicrobial mouthwashes is to reduce plaque and gingivitis. The American Dental Association 
(ADA) puts an ADA-Accepted seal on antimicrobial mouthwashes that reduce plaque and 
gingivitis better than brushing and flossing alone 30. Mouthwashes can be composed of various 
active ingredients that may or may not have antimicrobial agents. Available mouthwashes may 
include the following active ingredients: antibiotics, bisbiguanide, chlorine derivatives, essential 
oils, fluorides, oxygenating compounds, phenols, plant extracts, or quaternary ammonium 
compounds 31. Products that have earned the ADA Seal are those that contain 0.12% 
chlorhexidine gluconate (CHG) or a fixed combination of essential oils (EO) such as Listerine® 
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30. Several studies have been conducted on the effectiveness of different active ingredients on 
oral health; however, there are few studies that actually characterize the changes of the oral 
microbiota due to the main active ingredients in these products. 
1.3.1 Effectiveness of Active Ingredients 
When choosing a mouthwash or toothpaste to buy, the effect of it on its oral hygiene can 
be a main deciding factor. Depending on its main active ingredients, it can act as an antiplaque, 
antigingivitis, anticaries, desensitizing, or whitening agent. In order to know which mouthwashes 
or toothpastes are any of these agents they must be tested. Mouthwashes including essential oils 
have strong clinical evidence for efficacy against different oral biofilms bacteria 31, 32. They also 
have been shown to effectively act as both an antiplaque and anti-gingivitis agent 33. Studies 
testing various chlorhexidine varnishes as prevention for caries/biofilms were inconclusive; they 
were effective against different oral biofilms, but, present a number of unwanted side effects and 
should be prescribed with caution. It was recommended that further well-conducted randomized 
trails be completed before being recommended for caries/biofilm prevention 31, 34. Mouthwashes 
with 0.12% chlorhexidine or essential oils, and dentifrices containing triclosan with 2% Gantrez 
copolymer or stannous fluoride reduce gingivitis 33. Stannous fluoride/sodium 
hexametaphosphate provides antiplaque, antigingivitis, anticaries, and antisensitivity benefits 35.  
The composition of oral microbiota can change based on the main active ingredients of 
the mouthwash or toothpaste. These changes can possibly alter the composition of oral 
microbiota, possibly eliminating both bad and good bacteria. What researchers need to determine 
is what populations of oral microbiota flourish after use of these chemically different hygiene 
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applications. Several recent studies, mostly using culture techniques, have found reduction in 
various select oral microbiota. For example, chitosan mouthwash interferes with the adherence of 
all microorganisms in vitro 36. Xylitol in mouthwashes was found to reduce the number of 
Streptococci mutans 37. The Green Tea Extract in mouthwashes was also found to decrease the 
colony counts of Streptococci mutans and Lactobacilli 38. Cetylpyridinium chloride 
mouthwashes reduce plaque accumulation, gingival inflammation and also reduce 
Porphyromonas gingivalis and Fusobacterium nucleatum associated with halitosis 14, 39. 
Chlorhexidine (0.12%) has been found to reduce Aggregatibacter actinomycetemcomitans. 
Escherichia coli and Streptococcus mutans counts were also reduced when a combination of 
chlorhexidine gluconate and sodium fluoride were the main active ingredients in a mouthwash 11, 
40. Triclosan in toothpaste was found to significantly reduce the number of Candida albicans and 
Streptococci mutans, however its efficacy as a mouthwash had limited data 40. Antibacterial 
toothpastes containing stannous fluoride were found to significantly reduce bacterial viability in 
plaque left behind after brushing for up to 12 hours 41. Biotene, a dry mouth wetting agent 
containing lysozyme, lactoferrin, glucose oxidase, and lactoperoxidase, exhibited antimicrobial 
activity against Streptococcus mutans and Lactobacillus acidophilus, but was not effective on 
Candida albicans 42.  
Analysis of previous studies provides some insight into which ingredients act as 
preventative and whitening agents, and which species are decreased in numbers and counts. Most 
of these studies only assayed specific species, so that alterations in the vast repertoire of other 
species went unmeasured. Further research should examine the effects of the entire normal 
12 
 
microbiota and determine which species colonize and flourish after a specific treatment. My 
thesis research addresses this gap. 
1.4 Specific Aims 
The first specific aim was to design a human subject’s research proposal and 
questionnaire that met Wayne State University (WSU) requirements. This research thesis 
requires the participation of the WSU Institutional Review Board (IRB) committee, and 
therefore, protocols, consent, and case report forms were developed for expedited approval. A 
Dental Health Questionnaire (Appendix A) form was also approved and obtained for statistical 
analysis. This specific aim was completed and accepted by the IRB committee (IRB protocol 
number: 075914). The second specific aim was to optimize sample storage and DNA extraction. 
Proper storage and DNA extraction of spit samples required the testing of several storage buffers 
and lysis combinations. This aim was completed and a Saliva Storage Buffer (SSB) solution 
combined with Fungal Lysis Buffer (FLB) confirmed no cell growth or DNA degradation. The 
third and fourth specific aims include bacterial and fungal microbiome characterizations. Saliva 
DNA samples from the xerostomia versus healthy study arm were completely characterized by 
phylogenetic branch specific qPCR [24]. DNA from samples were stored for analysis by next-
generation sequencing. Saliva DNA sample from the nightly oral hygiene practice study arm 
were partially characterized. Fungal species in the xerostomia and healthy samples were 
identified by qPCR and melt curve analysis, coupled with selective sequencing, as described 
[25].  Statistical analysis to correlate compositions with patient data was performed with 
GraphPad Prism 6 and other software, and with Microsoft Excel add-on tools. 
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1.5 Significance 
The primary purpose of this investigation is to define differences in oral microbiota 
between healthy and xerostomia patients.  We hypothesize that there will be differences between 
the groups; if so, these differences will provide a basis for dealing with the problems associated 
with xerostomia. A better understanding of the altered microbiota of xerostomia patients should 
provide insights into more rational therapies. Also, characterization of combined bacterial and 
fungal biomes is novel and may provide insight into oral candidiasis in these and in other groups 
of patients. This will be done by microbial DNA extraction directly from saliva, using the mouth 
as an incubator for normal microbial compositions per individual. 
Secondary goals are to define day-to-day changes in oral microbiota in healthy 
individuals, and to measure the impact of nightly oral hygiene practices on oral microbiota the 
following day. We hypothesize that commercial mouthwashes/toothpastes alter the oral 
microbiome in ways that may not foster the outgrowth of potentially beneficial species, based on 
counter-productive use of douches in vaginal studies. A better understanding of the composition 
of the oral microbiota as a whole, based on nightly oral hygiene practices, should provide 
insights to which practice is most beneficial for fostering growth of beneficial oral microbiota. 
These oral hygiene practices are done at night, before bed and without any food or water 
between the nightly routine and the morning sample, to reduce the variables that change the oral 
microbiota throughout the day. The mouth is then used as an over-night incubator for primary 
colonies to become established based on their ability to flourish after the specific nightly oral 
hygiene practice.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Preliminary Trials & Saliva Storage/Lysis Buffers Methodology 
2.1.1 Sample Collection Strategy  
The xerostomia versus control study arm and the nightly oral hygiene study arm’s DNA 
were collected the same way. To achieve extraction of DNA directly from saliva from all the oral 
microbiota, a stable storage buffer combined with a productive DNA extraction method must be 
carefully chosen. For the convenience of the volunteers and the number of daily samples needed 
in the nightly oral hygiene study, saliva should be collected and stored until all samples are 
completed and returned to the lab for DNA extraction. The saliva sample could possibly sit in the 
buffer for at least 30 days. This buffer must not degrade cells and/or DNA from the saliva but 
also should not promote new cell growth either. The buffer chosen must be stable across several 
individuals, not inhibit or interfere with DNA extraction, and combined with the DNA extraction 
method of choice, they must allow maximum DNA extraction across several oral species. The 
storage buffer must also be non-toxic and chemically safe, in case small traces were to get on lips 
during collection. However, volunteers will be strongly advised to not pour the buffer in their 
mouths or consume it, no matter what buffer is chosen for the study.  
To find this ideal storage buffer and lysis combination, several storage buffers/lysis 
methods were tested from an aliquot of saliva from a single volunteer. Following the results of 
this comparison, the 2 best storage buffers were tested with lysis across 4 different individuals. 
Finally the best storage buffer was further tested on the prevention of cell growth and extraction 
across several species. 
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2.1.2 Initial Saliva Storage/DNA Extraction Testing 
A single volunteer’s aliquot of saliva was tested across 7 storage buffers: Qiagen 
RNAlater (Qiagen RNAlater RNA stabilization reagent, Qiagen Sciences, Maryland, USA), 91% 
isopropyl alcohol (IPOH), 95% ethanol (EtOH), 1 x Fungal Lysis Buffer A (FLBA) (contents 
listed in Appendix B) without potassium hydroxide (KOH), 1 x FLBA without KOH plus 
ethylenediaminetetraacetic acid (EDTA), saliva with no buffer, and regular 1 x FLBA with 
KOH, or a high SDS/alkaline lysis-phenol extraction 43.  
To compare the longevity of bacterial DNA in saliva in the storage buffers, each was 
tested at three time points: day 0 or same day processing, day 7, and day 30. Approximately 1.5 
mL of each of the storage buffers was added to 500 µL aliquots of saliva. On the day of 
processing, these were centrifuged at 16,060 x g, supernatants were discarded, and pellets were 
suspended in 500 µL FLBA with 5 µL KOH (100:1). All of the storage buffers were then 
incubated at 65°C for 2 hours and followed with centrifugation at 16,060 x g and collection of 
the supernatant. Approximately 250 µL of Fungal Lysis Buffer B (FLBB) (contents listed in 
Appendix B) was then added to the collected supernatant for neutralization (pH of approximately 
7.8). Half of the FLB supernatant collected was placed in a new sterile 2 mL tube and purified 
with buffer QG (Qiagen buffer QG buffer from Qiagen’s QIAquick Gel Extraction Kit, Qiagen 
Sciences, Maryland, USA). Buffer QG was added to fill the 2 mL tube, then centrifuged 10 min 
at 16,060 x g; the supernatant was bound to and washed with a Qiagen QIAquick spin column, 
according to the manufacturer’s protocol. The column was then left to air dry for 10 minutes 
followed by the addition of 200 µL of 1 x Tris-EDTA buffer (10 mM Tris pH 8.3, 1 mM EDTA; 
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TE). After the TE was in the column for 5 minutes, the eluate was collected through 
centrifugation at 16,060 x g and stored at -20°C until analysis. The remaining half of the 
neutralized FLB supernatant was stored at -20°C until analysis. 
An aliquot of purified DNA from each of the storage buffer variations with time periods 
(total of 42 variations) was assayed by qPCR with a few primers: a 16s bacterial universal 
primer, a primer to test for inhibition, and a phylogenetic branch-inclusive (PB) 16s 
Lactobacillus primer. Lactobacillus was chosen since it is a gram positive bacterium, more 
difficult to lyse and therefore a more stringent test of the buffers.  Molecules per reaction or Cq 
values were then compared for the top 2 storage buffers, those with best overall and best 
Lactobacillus titers and with least inhibition; these were then tested on across a few different 
individuals.  
2.1.3 Secondary Saliva Storage/DNA Extraction Testing 
After eliminating unacceptable saliva storage/DNA extraction methods from the initial 
experiment, one buffer from the initial testing and two additional new buffers were tested on 
their stability across multiple individuals. Four volunteers each provided an aliquot of saliva for 
testing stability across 3 storage buffers: 91% IPOH, Saliva Storage Buffer (SSB; Appendix B) 
and Qiagen’s buffer QG. Stability of DNA and extraction efficiencies were compared as 
described above. 
An aliquot of purified DNA from each of the storage buffer variations and time periods 
from each individual (total of 20 variations) were assayed by qPCR with several primers: a 16s 
bacterial universal primer, a primer to test for inhibition of the purified DNA in its buffer, and 
17 
 
phylogenetic branch-inclusive (PB) 16s Lachnospiraceae primers 43. Molecules per reaction 
(calculated by CFX Manager™ Software v3.1) or Cq values were compared for the type of 
storage buffer/processing method to use in both arms of the project. 
2.1.4 Cell Viability Testing in SSB & IPOH 
The viability of the saliva cells in the select buffers was tested to determine whether any 
bacterial growth was occurring what might alter the initial populations, over a 28 day time 
period. The buffers of choice, determined from the previous experiments, were IPOH and SSB 
and the control buffer was 1x PBS (Appendix B). These three buffers were tested on two 
different individuals’ saliva. For direct comparison of the three buffers across the 28 days a 
single 36 ml aliquot of each buffer was compared for each subject. An aliquot of 4.5 ml of each 
subject’s saliva was added to each of the buffer tubes. These tubes were then tested by CFU on 
Trypticase Soy Agar (TSA; Appendix B). and aliquots were lysed with FLB for 8 different time 
points (t = 0 [initial], 1 hour, 1 day, 5 days, 9 days, 13 days, 21 days, and 28 days) during the 28-
day testing. The initial time period (t = 0) is samples taken immediately after the saliva sample is 
added to the buffer. These tubes were tested using two separate analyses. The first was cell 
counting by streaking on select media. This experiment will show if there is any growth or death 
of the saliva cells. The DNA was extracted (FLB method) from cells still alive in either the IPOH 
or SSB buffer, amplified and sent out for sequencing. The second experiment requires extraction 
of the saliva’s microbial DNA and qPCR to test for any changes in the species of the salvia 
sample.  
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When counting cells or colony-forming units (CFU), samples were serially diluted in 
PBS (-1, -2, and -3) and 10 µL of each were spread uniformly with a sterile glass rod in a 
quadrant on TSA. The plates were then incubated anaerobically in a candle jar at 37°C overnight 
and colonies were counted in the quadrant that had the closest to 100 colonies, and calculations 
were done to get the CFU/mL in each buffer at each time point. Pictures of each of the plates 
were also taken. Cells still alive in either buffer were lysed using the FLB method described 
previously in Section 2.1.1, except cells were scraped from agar using a sterile pipet tip and 
mixed in the FLB solution. Then the DNA of these cells were amplified using qPCR with the 
bacterial universal primer (16s) and prepped to be sent out for sequencing (method described in 
Section 2.3.5). 
During the DNA extraction portion, an aliquot of 4 mL was removed from the original 
aliquot and centrifuged for 30 minutes at 16,060 x g. The buffer was then discarded and 500 μL 
of FLB-A + KOH was added to the pellet, and processed using the FLB method (mentioned 
above in section 2.1.2). Samples that originally contained SSB, however, did not need any FLB-
B because they were already neutral. To directly compare the three samples, each sample was 
adjusted to a final volume of 850 μL with appropriate amounts of 1 x TE. Each of the samples 
was then assayed by qPCR with two broad-spectrum bacterial primers:  one spanning variable 
domains 3-5 of the 16S ribosomal RNA gene, (Bu10) and the other spanning the internal 
transcribed spacer between the 16S and 23S ribosomal RNA genes (BuITS). Melt peak results 
were compared to monitor for overt changes in bacterial compositions. 
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2.1.5 Species DNA Extraction with SSB/FLB Test 
To determine if our extraction protocol and buffers compared well with commercial kits, 
the chosen storage/lysis buffer (SSB/FLB) was tested against FastDNA™ KIT (MP 
Biomedicals). The FastDNA™ Kit quickly and efficiently isolates high quality genomic DNA 
from plants, animals, bacteria, yeast, algae, and fungi using Lysing Matrix A (garnet and one 1/4 
inch ceramic bead) for cell lysis and a silica-based method for the purification process. To 
compare these two extraction methods against each other, equal volumes of 10 different species’ 
DNA were extracted using both methods. The 10 species and collection methods are listed in 
Table 5 in Section 3.1.4. Notably, we included several species of Streptococcus, which has a 
reputation for poor extraction efficiency using commercial kits. The extracted DNA was 
compared using the 16s bacterial universal primer and an inhibitory primer (DR3) in qPCR. 
The 10 species were collected and grown by incubation for 48 hours in 37°C in a 2 mL 
tube with 500 μL of LIB + supplements broth (Appendix B). A control tube was also made with 
the same 500 μL aliquot that the other tubes received and also processed with both methods. 
After incubation for 48 hours, an aliquot from each species tube adjusted to an optical density 
(A600) and then at similar cellular densities species’ aliquots were individually prepped for 
extraction. To do this, the cells were diluted 50-fold in new LIB media broth (196 μL of LIB 
media and 4 μL of cells grown in LIB) and read in a Model 25 spectrophotometer (Beckman, 
CA), blanking against LIB media only. Volumes were then adjusted, by adding small amounts of 
LIB to get an A600 reading of 0.079 ± 0.0043.  
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Samples were processed with the FastDNA™ Kit as outlined in its manual with the 
modifications below. Aliquots of 100 μL of cells suspended in LIB (Appendix B) were 
transferred into a new tube and centrifuged. The supernatants were discarded and 100 μL of 
deionized water was added and the cells were re-suspended. This combination of cells and 
deionized water were then moved into Lysing Matrix A tube. Then 1.0 mL of CLS-TC Cell 
Lysis Solution was added to the Lysing Matrix A tube and was homogenized on a Krafttech™ 
(1/4 Sheet Palm Sander, PS160CA), because lack of FastPrep Instrument, for 40 seconds at 200 
oscillations/second. Each tube was then centrifuged at 16,060 x g for 8 minutes to pellet debris 
and the supernatant was transferred to a 2.0 mL micro-centrifuge tube. Equal volume of Binding 
Matrix (1.0 mL) was then added to the tube and it was then incubated with gentle agitation for 5 
minutes at room temperature on a rotator. After agitation the tube was centrifuged at 16,060 x g 
for 10s to pellet the Binding Matrix and then the supernatant was discarded. In the next step, 500 
μL of prepared SEWS-M was added and the pellet was re-suspended gently using the force of 
the liquid from the pipet tip. This followed with centrifuging at 16,060 x g for 1 minute and 
discarding supernatant, and then centrifuging at 16,060 x g for 10s and removing residual liquid 
with a small pipet tip. The DNA was eluted by gently re-suspending Binding Matrix in 100 μl of 
DES and incubating for 5 minutes at 55°C in water bath. The tube was then centrifuged at 16,060 
x g for 1 minute. Finally, eluted DNA was transferred to a clean tube and appropriate amounts of 
1 x TE was added to give a final volume of 800 μL and then stored at -70°C. The addition of TE 
to get a final volume of 800 μL is done so that all samples have the same final volume.  
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DNA extraction protocol via SSB/FLB:  an aliquot of 100 μL of each of the species’ cells 
grown in LIB were added to a 15 mL tube containing 2 mL of SSB and incubated at room 
temperature for 1 week. After the cells sat in SSB for 1 week, the tube was then centrifuged at 
16,060 x g for 15 minutes and the supernatant was discarded. The pellet was then left to air dry 
in the tube for 10 minutes, and then processed with FLB (method described in section 2.1.2). 
After being processed, TE was added to give a final volume of 800 μL and the sample was then 
stored at -70°C.  
2.2 Quality Control Methods 
2.2.1 Saliva Storage Buffer Contaminants Methodology 
The long-term storage of saliva in 4 mL of SSB buffer in the 15 mL tubes could 
introduce contamination. To test whether this is an issue or not, 500 µL of SSB was evenly 
distributed across the plate via a sterile glass rod, on two types of Agar: YPD+AMP and MLT 
Max (both contents can be found in Appendix B). The aliquot of SSB came from the same lot 
used for patient samples and was incubated for more than 30 days. A total of 6 plates were 
tested, 3 of each type using 3 different tubes of SSB. The YPD + AMP plates were incubated at 
room temperature and the MLT Max plates were incubated in candle jars at 37oC for 5 days. 
There was no growth on any of the plates. 
2.2.2 DNA Extraction Contaminants Methodology 
The process of extracting DNA from saliva that was stored in the SSB buffer for 30 days 
could contaminate the samples. To demonstrate that contamination was unlikely, 12 mock 
samples, leftover tubes of 4 mL of SSB that never received a saliva inoculum and held SSB from 
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more than 30 days, were processed with FLB using the same process mentioned in section 2.1.2. 
FLB samples were then tested at several dilutions in qPCR using the 3 universal primers and an 
inhibitor testing primer.  
2.2.3 Air Contaminants Methodology 
The universal primers are very sensitive and could potentially detect air contaminants 
introduced during the qPCR setup. Working in a lab where bacterial and fungal species are 
constantly being streaked for growth, there can be a lot of airborne species, especially fungal and 
mold. To test the possible air contaminants at my bench, 3 YPD +AMP Agar plates sat on with 
lids off on my lab bench for several days. Only two colonies grew; DNA amplified from these 
with FungalITS primers were sequenced to compare with targets derived from patient samples.  
2.2.4 DNA Degradation Test 
Each plate of samples endured multiple freeze-thaw cycles in order to complete different 
primer qPCRs. This cycling could degrade the DNA templates. To test whether the DNA was 
degraded, one of the master plates, XC1, was assayed with the same Bu10 primer after all of the 
other primers were completed. Therefore, the initial Bu10 run molecules/reaction is directly 
compared to the values obtained from a run at the end of the study.  
2.3 Molecular Characterization Methods 
2.3.1 Phylogenetic branch-inclusive qPCR Primers Construction 
Bacterial and fungal compositions were initially analyzed by qPCR 43, 44 45, using, 
methods similar to those described by Lambert et al. for Phylogenetic branch-inclusive (PB) 
qPCR 44. Phylogenetic branch-inclusive (PB) qPCR uses PB primers that target a specific 
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phylum or family or genus, making them far more inclusive than species-specific primers 44. The 
collection was initially validated with target and non-target single species 43.  An aliquot of 
purified DNA was assayed by qPCR with 3 universal (2 bacterial and 1 fungal) and phylogenetic 
branch-inclusive (PB) primers and PCR conditions as described previously. Additional primers 
used were Betaproteobacteria ITS in anticipation of oral Neisseria and Derxia, Streptococcus 
ITS in anticipation of oral Streptococcus, Bacteroidetes ITS phylum primer in anticipation of 
oral Capnocytophaga, Bacteroides, Flavobacteria and Prevotella, Actinobacteridae 16s in 
anticipation of oral Actinomyces and Luteococcus, Megashaera 16s in anticipation of oral 
Veillonella, Lactobacillaceae 16s and ITS in anticipation of oral Granulicatella, and 
Enterococcaceae 16s in anticipation of oral Gemella. All primers with additional information 
about each primer can be found in Appendix B. 
Whether contaminants in a given sample inhibited or reduced the efficiency of qPCR was 
determined by testing each with exogenous template and primers. We used an amplicon derived 
from Deinococcus radiodurans, chosen because it amplifies with broad spectrum primers but not 
with any PB primers, since it is a member of a distinct phyla (Deinococcus-Thermus). The 
species are not normally found in the human body or our saliva samples 46.  Inhibition of a DNA 
sample in qPCR was determined using primer DR3 (Appendix D), specific for the 
species Deinococcus radiodurans. In this inhibition testing qPCR, a fixed amount of amplicon 
(7.5 ng/ 1 µL), made by ampifying D. radiodurans genomic DNA with DR3, was added to the 
mastermix. This was distributed to all wells, except negative control wells. Standard wells 
received no sample, only the amplicon mastermix.  Samples were then added to all experimental 
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wells. qPCR was performed with DR3.  The distribution of Cq values of wells receiving both 
sample and amplicon were compared to those with amplicon only. Wells whose Cq values were 
more than 2 standard deviations from the average amplicon-only wells were considered to have 
some level of inhibition, and would require retesting after further purification or after diluting 
out contaminants causing the inhibition. 
2.3.2 Biorad’s CFX Program-Cq Call Methods 
The Biorad’s qPCR CFX program has three different methods for calling Cq values for 
each qPCR run: Regression, Single Threshold-Auto, and Single Threshold-Custom. To 
determine which method was the best for calling Cq values across multiple experiments, I 
calculated the average and standard deviation of the Cq values from each dilution of the spike 
amplicon, from 21 separate qPCR runs with Bu10, for each of the three methods. Then these 
dilution averages were plotted against the log of its molecules/µL, giving the new averaged 
standard slope per Cq call. The slope was then used to calculate the percent of efficiency for the 
qPCR, %E = (10^ (-1 / slope) -1) * 100.  
2.3.3 Determining Molecules/µL of DNA Methods 
The Biorad’s CFX program allows the input of serially diluted standards (spike, usually 
dilutions 10-4 to 10-9 containing 7.10 x 104 to 2.10 x 106 molecules/µL for each qPCR run. The 
program then generates titers (molecules/reaction) for each sample individually derived from Cq 
values. The percent compositions of target microbial groups for each sample can then be 
calculated and compared between xerostomia and non-xerostomia groups using GraphPad 
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Prism® 6 statistical software. I did not convert molecules per sample to cells per sample, because 
the copy number of ribosomal RNA genes per genome varies from 1-15 depending on species 47. 
The number of molecules/µL of the undiluted spike was calculated using by determining 
the values of the mass of the spike in ng/µL and the length of the spike in bp, and converting 
those values using the New England Biolabs Inc.’s dsDNA: Mass to Moles Convertor Calculator 
(http://nebiocalculator.neb.com/#!/dsdnaamt). Once the molecules/µL of the spike was found, it 
was easily converted into the correct dilutions used in qPCR (10-4). The mass of the spike 
(ng/µL) was determined using gel electrophoresis and a 100 bp ladder (GoldBIO.COM 100 bp 
Plus TM DNA Ladder, CAT#D003-500).  10 µL of two-fold dilutions of amplicon was loaded 
into 2 % Agarose LE Gel (contents can be found in Appendix B) and electrophoresed in 1 x SB 
Buffer (contents in Appendix B) at 100 Volts for 45 minutes. The dilution of spike the intensity 
of a similar size band of the ladder was used to approximate its mass in ng/5µL of spike.  
2.3.4 Oral Bacterial and Fungal Library Construction 
I assembled a repository of 364 live colony purified cultures from saliva of both healthy 
and xerostomia volunteers, with matching DNA freezer stocks, listed in Appendix C. To start 
this process, several 10 µL aliquots from both healthy and xerostomia saliva flow test tubes less 
than 24 hours old, were streaked using the quadrant streaking technique on three types of Agar: 
Human Blood Trypticase Soy Agar (TSA), Rogosa Agar, and MesLib (MLT) Agar (all agar 
contents can be found in Appendix B). Plates were incubated anaerobically in 37oC for 48 hours. 
In the next step referred to as the “pie plates”, single isolated colonies were picked from the first 
streaked plate onto a fresh agar plate of the same media, which is divided into several “pie 
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slices”, one for each isolated colony, and picked colony is then re-streaked using the quadrant 
form and incubated anaerobically in 37oC for 48 hours. After cell growth, individual isolated cell 
colonies were picked for making “nickels”; nickel-sized circles were drawn on the bottom of the 
agar plates and each nickel is a different isolated colony. Rubbing the single isolated colony all 
over the circle, overlapping parts of the circle multiple times, results are in confluent growth. 
Plates were then incubated anaerobically in 37oC for 48 hours. Once confluent nickels were 
grown, FLB and Milk/Yeast Extract/Glycerol’s (MYEG) (Appendix B) were made. First using a 
p10 pipette tip, a barely visible amount of the nickel is picked and put into 100 µL of FLBA and 
KOH (100:1) in a 96 well plate, to make the FLB sample for qPCR. Then the rest of the nickel 
was harvested and suspended in a 1.5 mL tube with 1 mL of MYEG mixture (Appendix B). The 
nickel in the MYEG mixture is then mixed using the pipette and 100 µL aliquot is taken out and 
put into the MYEG 96 well plate that matches the FLB plate. All nickels were photographed and 
colony morphologies were recorded. Once all the nickels were made into FLB and MYEG 
stocks, the MYEG plates and tubes were stored in a -70oC freezer. The FLB is processed as 
described in Section 2.1.2. The finished FLB product is then stored in the freezer until qPCR 
analysis. FLB’s of saliva cell colonies were diluted into 50 µL of 1 x TE using a pin replicator 
(Scinomix, MO), which transfers ~0.5 to 1 µL, sterilized with a 5 min exposure to germicidal 
ultraviolet light at a distance of 21 cm. These dilution master plates were then tested using 3 
broad-spectrum primers (both bacterial universal primers and the fungal universal primer). 
Samples from qPCR that had unique melting temperatures for combined bacterial universal 
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primers were prepped and sent out for sequencing (method described in next section, Section 
2.3.5). 
2.3.5 Sequencing Methods 
Two to three samples representing unique melt profiles across several experiments for 
each primer were selected for sequencing. Samples were tested to see if they were positive and 
composed of single discrete bands by gel electrophoresis: 10 µL of each post qPCR sample with 
dye was loaded into individual wells of 2% Agarose LE Gel and ran in 1 x SB buffer at 100 
Volts for 30 minutes. If samples showed no bands or multiple bands, they were not sent out for 
sequencing. Samples with single discrete bands were enzymatically “cleaned” by the Exo-Sap 
method 48.  Depending on band intensity, 3-5 µL of sample was adjusted to 5 µL with sterile 
deionized water and added to 5 µL of the Exo-Sap. This was made for an entire 96 well plate as 
follows: 2.4 µL of Shrimp Alkaline Phosphatase (SAP) (Tested User Friendly™, 1UN/µl, Lot: 
114511), 24 µL Exonuclease 1 (Thermo Scientific, 20,000 U, Lot. 00132863), 48 µL of 10 x 
PCR Buffer minus Mg (GIBCO-BRL, Lot No. 1090571), 192 µL of 25 mM MgCl2 (Promega, 
Madison, WI, USA, A351B), 216 µL of Reverse Osmosis Water (ROW). Samples were 
incubated at 37oC for 15 minutes, and then heat-inactivated at 65oC for 30 minutes. Primers were 
then added (25 pmoles in 5 µL TE, adjusted with 25 mM MgCl2 to counter the EDTA in the TE 
buffer. Samples were stored in a -70oC freezer until they were shipped to GenScript USA Inc. for 
Sanger DNA sequencing 49 using “Big dye” chemistry 50, 51.  
Sequences that were returned from GenScript were then matched using two online 
microbial sequence databases: RDP Seqmatch (https://rdp.cme.msu.edu/seqmatch) and the NCBI 
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BLAST® (http://blast.ncbi.nlm.nih.gov/Blast.cgi). For analysis of the 16S ribosomal RNA gene 
amplicons, zipped folders containing the fas and ab1 files were uploaded into the RDP pipeline 
for processing. Aligned sequences were seqmatched to the top 3 database entries (>1200, 
Quality: Good). For the NCBI BLAST® sequence analysis, the “Nucleotide Blast” program was 
used to find the species matches, testing several databases (nr), Whole-genome shotgun contigs 
(WGS). For primers Bu10, EntC, Lachno2, LbITS, StaphITSO, and StrepITSO, the WGS 
database was limited to Firmicutes. For primers Actino, BProITS, and OidesITS, the target was 
limited to Actinobacteria, Proteobacteria, and Bacteroidetes, respectively. Once results were 
given, samples matches with species that had a greater than or equal to 97% identity and query 
coverage were accounted for within each primer set. For the remaining primer, Mega, amplicons 
that were sent out for sequencing, the NCBI BLAST® was used for analysis of the sequenced 
species. The “Nucleotide Blast” program was used to find the species matches. Once directed to 
“Nucleotide Blast”, the database was “nr”, limited to Bacteria. Once results were given, samples 
matches with species that had a greater than or equal to 97% identity and query coverage were 
accounted for within each primer set. 
The fungal ITS sequences were analyzed by aligning the reads using Mega 6 Muscle 
Alignment. This identified poor base calls particularly at the ends. Ends were trimmed to 
conservative shared calls; poorly aligning or short reads were discarded. Remaining sequences 
were Megablasted at the NCBI website against both nr and WGS databases to identify closest 
matches.  
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2.4 Study Setups & Experimental Plans 
2.4.1 Volunteer Enrollment 
Xerostomia and healthy volunteers will be identified and enrolled with the help of a 
participating dental office, and additional healthy volunteers will be self-enrolled by paper and 
Internet postings on Wayne State University Pipeline. Nightly oral hygiene practice volunteers 
were enrolled by paper and Internet postings on Wayne State University Pipeline. The 
enrollment lasted approximately 35-45 minutes. During enrollment, volunteers were asked to 
sign a consent form, fill out a dental health questionnaire (Appendix A) and perform a saliva pH 
test and two five-minute Saliva flow tests (unstimulated and stimulated). Because a focus of this 
project is xerostomia, we used stimulated and whole saliva (Saliva) as samples as our diagnostic 
of xerostomia. In the pH Saliva test, volunteers stuck an end of short-range pH paper (Hydrion 
Papers 4.5 to 7.5, Micro Essential Laboratory, N.Y.) in their mouth to get it moist and then 
compare the color to the pH color standards. To perform the unstimulated saliva flow test, 
volunteers were asked to try to not create any saliva flow and to drool into a 2.0 mL tube instead 
of swallowing for duration of 5 minutes. To perform the stimulated saliva flow test, volunteers 
were asked to chew on a 2” by 2” piece of sterile Parafilm® (Menasha, WI) and to saliva in a 15 
mL tube instead of swallowing for a duration of 5 minutes. The unstimulated and stimulated 
saliva flow tests were both recorded in mL/5 minutes.   
2.4.2 Xerostomia vs. Control Study Arm Sampling Method 
Volunteers were given instructions and materials to collect three Saliva samples on three 
consecutive days at their homes, upon awakening and before eating, drinking, or brushing, to 
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minimize those variables. Saliva is collected in a 15 mL sterile tube with Saliva Storage Buffer 
(SSB), safe to participants.  Saliva is stable to sit in buffer at room temperature for up to 30 days. 
The inclusion criteria for xerostomia participants were as follows: 18 years or older, participants 
must self-report subjective “dry-mouth” feeling over 3 months, and salivary flow test indicative 
of hyposalivation: stimulated whole saliva flow rate below 0.5 mL/min 20. The inclusion criteria 
for healthy control volunteers were: participants must not have self-reported subjective “dry-
mouth” feeling in the previous 3 months or any of the following diseases: Patients with the 
following diseases are excluded: Sjögren’s Syndrome, or enrollment visit symptoms of 
xerostomia, head-and-neck radiation therapy, or trauma to salivary glands, and saliva flow tests 
must report values denoting no xerostomia: Salivary flow test indicative of non-hyposalivation 
(measurement of unstimulated whole saliva (UWS) above 0.12-0.16 mL/min and stimulated 
whole saliva flow rate above 0.5 mL/min20. The exclusion criteria for both groups of the study 
included the use of antibiotics 3 months prior to enrollment in the study. 
 
2.4.3 Nightly Oral Hygiene Practices Arm Sampling Method 
The exclusion criteria for volunteers of the study included the use of antibiotics 3 months 
prior to enrollment in the study. Volunteers were given instructions (listed below) and materials 
to collect 30 Saliva samples on at their homes. It is stressed that the participants do not eat, drink, 
or brush after the specific nightly oral hygiene procedure is performed until the morning sample 
is taken, upon awakening and before eating, drinking, or brushing, to minimize those variables. 
The nightly variations in oral hygiene practices instructions: 
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a. Days 1-5: no nightly mouthwash or brush, then morning 2 min brush with provided 
Crest Pro-Health toothpaste and brush after sample collection.  
b. Days 6-10: nightly mouthwash with 15- 20 mL Listerine Total Care Mouthwash 
without brushing (for 60 seconds of vigorous swishing), then morning 2 min brush with 
provided Crest Pro-Health toothpaste and brush after sample collection.  
c. Days 11-15: nightly mouthwash with 15- 20 mL Crest 3D White Luxe Mouthwash 
without brushing (for 60 seconds of vigorous swishing), then morning 2 min brush with 
provided Crest Pro-Health toothpaste and brush after sample collection.  
d. Days 16-20: nightly toothpaste with a 1-inch strip of Crest 3D White Toothpaste and 
provided brush (brushing for 2 minutes), then morning 2 min brush with provided Crest 
Pro-Health toothpaste and brush after sample collection.  
e. Days 21-25: nightly toothpaste with a 1-inch strip of Colgate Optic White Toothpaste 
and provided brush (brushing for 2 minutes), then morning 2 min brush with provided 
Crest Pro-Health toothpaste and brush after sample collection.  
f. Days 26-30: no nightly mouthwash or brush, then morning 2 min brush with provided 
Crest Pro-Health toothpaste and brush after sample collection.  
After the sample is taken, volunteers are asked to brush their teeth with the provided 
toothpaste and toothbrush. Saliva is collected in a 15 mL sterile tube with Saliva Storage Buffer 
(SSB), safe to participants.  Saliva is stable to sit in buffer at room temperature for up to 30 days. 
If participants forget on any given night to perform the indicated rinse, non-rinse, or brush, they 
will simply skip sampling the next morning and resume the schedule the following night. They 
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will perform the full 5 days of sampling, even if that requires 6 or more days because of skipped 
days. If any product causes irritation, or any signs of oral infection or pain, participants will be 
instructed to stop using it, and to see their dentists. 
2.4.4 Sample DNA Extraction Method 
After the Saliva samples sit in the SSB for at least 30 days the DNA is extracted. To 
process the saliva samples and extract their bacterial and fungal DNA a Fungal Lysis Buffer 
(FLB) was used. The samples are centrifuged and supernatant discarded. Pellet is suspended in 
fungal lysis buffer A (FLBA) mixture with KOH, a high SDS/alkaline lysis-phenol extraction, 
and then incubated at 65°C for 2 hours and followed with centrifugation at 16,060 x g and 
collection of the supernatant. Addition of fungal lysis buffer B (FLBB) was not needed for 
neutralization (pH of approximately 7.8), because it was already neutral. The samples were 
stored at -20°C until assayed with qPCR. 
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CHAPTER 3: RESULTS 
3.1 SSB/FLB for Saliva Storage/Lysis Buffer 
3.1.1 91% IPOH/FQ Prevailed in Initial Storage/Lysis Combinations 
The 14 different saliva storage buffers/DNA extraction combinations (listed in Table 2) 
were tested from a single volunteer’s aliquot of saliva, to compare the stability and longevity of 
the saliva microbial DNA in each buffer by running a qPCR using a bacterial universal primer 
(Bu10), a primer to test for inhibition (DR3), and a branch-inclusive 16s primer specific for 
Lactobacillus species (LbITS). The goals for this experiment is to pick a combination or two that 
show high titers (amount of DNA) for this individual tested for multiple time periods and the 
sample must not be inhibited. Any samples that may show inhibition to samples or may be 
negative at day 30 should not be considered for the study. 
The total bacterial titers for each of the combinations, using a 16s bacterial universal 
primer (Bu10), combined with the inhibitory primer data will help eliminate undesirable 
storage/DNA lysis buffers. Table 2 presents the total bacterial titer, inhibitory values, and 
Lactobacillus Cq values for the 14 combinations tested in the primary salivary storage/DNA 
extraction buffer test on a single aliquot of saliva from one individual. The best dilution of the 
combinations with the highest number of molecules/reaction was used compared for analysis. 
There were 5 storage/extraction combinations that did amplify day 30 samples with the universal 
primer: 91% IPOH/FLB, 95%EtOH/FLB, FLBA-KOH/FLB, FLBA+KOH/FLB, and RNAl/FQ. 
From these, only FLBA+KOH/FLB showed large inhibition with a dCq value of 8.83, this 
inhibition could have given a false negative. The combinations that had high bacterial titers and 
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low inhibition (<2.00) at day 30 are: 91%IPOH/FQ (7.49 and 0.25, respectively), 95%EtOH/FQ 
(7.05 and 1.23, respectively), RNAl/FLB (5.37 and 0.30, respectively), and Spit/FLB (7.92 and 
1.97, respectively). Those combinations also gave desirable Cq values (<24) for Lactobacillus. 
Overall from the 14 saliva storage/DNA extraction buffers tested, 91%IPOH/FQ showed the 
lowest amount of inhibition, had a high return on bacterial molecules per reaction, and had a Cq 
value <24 for Lactobacillus.  
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Table 2. Total bacterial titers and inhibition values for day 30 of 14 storage/DNA lysis 
combinations tested on a single individual’s saliva aliquot. 
Storage/Lysis 
Dilution 
of Sample 
Bacterial 16s 
Universal 
Primer 
Bacterial 16s 
Universal 
Primer 
Lactobacillus 
16s Primer 
Inhibition 
Primer 
Molecules/ 
Reaction 
Molecules/ 
mL Saliva 
Cq Value dCq Value 
91%IPOH/FLB 10-1 1.31E+01 3.9E+05 27.49 0.44 
91%IPOH/FQ undiluted 2.88E+07 4.6E+10 23.08 0.25 
95%EtOH/FLB 10-1 1.31E+01 3.9E+05 26.60 2.22 
95%EtOH/FQ undiluted 1.12E+07 1.8E+10 21.68 1.23 
FLBA-KOH/FLB 10-1 1.31E+01 3.9E+05 26.10 2.51 
FLBA-KOH/FQ undiluted 6.31E+05 1.0E+09 21.64 2.05 
FLBA+EDTA/FLB 10-1 7.19E+06 2.2E+11 19.86 2.25 
FLBA+EDTA/FQ undiluted 1.12E+06 1.8E+09 19.39 2.31 
FLBA+KOH/FLB 10-1 1.31E+01 3.9E+05 24.47 8.83 
FLBA+KOH/FQ undiluted 2.56E+06 4.1E+09 30.47 2.55 
RNAl/FLB 10-1 2.36E+05 7.1E+09 22.62 0.30 
RNAl/FQ undiluted 1.31E+01 2.1E+04 18.90 0.10 
Spit/FLB 10-1 8.34E+07 2.5E+12 22.81 1.97 
Spit/FQ undiluted 9.08E+06 1.5E+10 20.06 2.43 
Values 1.31E+01 (molecules/reaction) and 3.9E+05 (molecules/mL saliva) were used for samples 
that were below detection level in qPCR. The full names of the storage/lysis combinations are as 
follows: 91% isopropyl alcohol with FLB lysis (91% IPOH/FLB), 91% isopropyl alcohol with FLB 
lysis followed by QG prep (91% IPOH/FQ), 95% ethanol with FLB lysis (95% EtOH/FLB), 95% 
ethanol with FLB lysis followed by QG prep (95% EtOH/FQ), 1 x Fungal Lysis Buffer A without 
potassium hydroxide with FLB lysis (FLBA-KOH/FLB), 1 x Fungal Lysis Buffer A without 
potassium hydroxide with FLB lysis followed by QG prep (FLBA-KOH/FQ), 1 x FLBA without 
KOH plus ethylenediaminetetraacetic acid with FLB lysis (FLBA+EDTA/FLB), 1 x FLBA without 
KOH plus ethylenediaminetetraacetic acid with FLB lysis followed by QG prep 
(FLBA+EDTA/FQ), 1 x Fungal Lysis Buffer A with potassium hydroxide with FLB lysis 
(FLBA+KOH/FLB), 1 x Fungal Lysis Buffer A with potassium hydroxide with FLB lysis followed 
by QG prep (FLBA+KOH/FQ)Qiagen RNAlater RNA stabilization reagent with FLB lysis 
(RNAl/FLB), Qiagen RNAlater RNA stabilization reagent with FLB lysis followed by QG 
prep(RNAl/FQ),  Saliva with no buffer with FLB lysis (saliva/FLB), and Saliva with no buffer with 
FLB lysis followed by QG prep (saliva/FQ). 
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3.1.2 Saliva Storage Buffer is Comparable to IPOH 
The buffers 91%IPOH, Saliva Storage Buffer (SSB), and Qiagen’s buffer QG (QG), 
combined with DNA extraction methods, were assayed amongst 4 individuals’ saliva samples by 
using qPCR with a universal primer, inhibition testing primer, and a Lachnospiraceae species 
primer. The goals for this experiment is to pick a combination or two that show high titers (amount of 
DNA) for this individual tested for multiple time periods and the sample must not be inhibited. The 
universal bacterial primer, Bu10, QPCR results from day 30 samples (Figure 1) suggests that 
SSB combined with FLB is the best method, giving high average log titer values and the smallest 
standard deviation from the 4 individuals 9.60 ± 0.59, respectively. The next best buffer/lysis 
combination is 91% IPOH/FLB with average log titer values of 9.70 ± 0.73. SSB/FLB has a 
lower standard deviation than the 91% IPOH/FLB combination.
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Figure 1. Bacterial titers of possible 
storage/lysis buffers from day 30 
samples. qPCR was ran using a 16s 
universal bacterial primer, Bu10. An 
aliquot of Saliva from 4 different 
subjects sat in buffer for 30 days 
before prepped for lysis.  
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The day 30 buffer/lysis saliva samples were checked for inhibition by QPCR with primer 
DR3 (Section 2.3.1; Appendix D). A table with the dCq values and average dCq values of each 
buffer across individuals is located in Table 4. The total average dCq across all day 30 samples is 
0.82 ± 0.52. All of the buffer/lysis preps, except QG, have average dCq values <1.0, indicating 
that they were free of PCR inhibitors. A 1-way ANOVA Friedman test gave a P value of 0.0124 
and the Dunn’s multiple comparisons test showed that QG was significantly different than the 
standard. 
  
3.1.3 Both SSB & IPOH Prevent New Cell Growth 
The two best saliva storage buffers (SSB and IPOH) and a control buffer, sterile saline 
buffer (PBS), were tested for new cell growth (via colony forming-unit [CFU]) and by qPCR 
analysis with bacterial universal primers for 8 time periods across 28 days.  The percentage of 
cells alive, Table 4, was calculated by counting the number of colonies in the quadrant that had 
approximately 100 cells, times the dilution factor, times 100 to bring the 10  by amount of µL 
plated to get the cells per mL still alive. Then the number of cells per mL still alive was divided 
by the initial value of cells per mL alive and then multiplied by 100 to bring the 10 µL plated to 
Table 3. Levels of inhibition of qPCR of saliva DNA among five types of storage and extraction buffers. 
  IPOH/FLB IPOH/FQ SSB/FLB SSB/FQ QG 
Volunteer 1 0.6 0.3 0.7 0.9 1.2 
Volunteer 2 0.6 0.3 0.4 0.7 2.3 
Volunteer 3 0.8 0 0.4 0.7 0.7 
Volunteer 4 0 0.3 1.1 0.8 1.1 
Average 0.50 ± 0.35 0.23 ± 0.15 0.65 ± 0.33 0.78 ± 0.10 1.33 ± 0.68 
An aliquot of Saliva from 4 different subjects sat in buffer for 30 days before prepped for lysis. All 
samples are a 10-1 dilution. 
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1 mL. IPOH immediately kills 
all cells and prevents growth 
from happening. In SSB cells 
did not die immediately, but 
in fact slowly die off. The 
cells that remained alive in 
SSB after several days were 
processed, amplified with 
qPCR using the bacterial universal primer (16s), sequenced, revealing that they were 
Streptococcus salivarius and Staphylococcus aureus subsp. aureus. 
Comparing the melt peaks from qPCR for each of the time points, listed previously, is a 
good indication on whether the dominant species are changing over time. Both of the bacterial 
universal primers were used. The 16s bacterial universal primer showed promising results for 
both buffers tested. SSB, Figure 2 (A & B), had little to no variation in melt temperatures across 
the days for both subjects. IPOH, Figure 2 (C & D), also had no variation between melt peaks for 
both subjects tested.  
  
Table 4. The percentage of cells alive in the potential saliva storage 
buffers across 28 days. 
  Subject #1 Subject #2 
Time in buffer 
(days) SSB IPOH PBS SSB IPOH PBS 
0 100 0 100 100 0 100 
0.04 8 0 104 54 0 111 
1 79 0 642 30 0 147 
5 2 0 123 7 0 350 
9 2 0 172 3 0 361 
13 0.2 0 97 1 0 TNTC 
21 0 0 5218 0 0 TNTC 
28 0 0 TNTC 0 0 TNTC 
Percentages were based off of the initial time (0) and were 
calculated using the colony forming-units. 
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Figure 2. Bu10 melt curves for cells lysed from SSB and IPOH across 28 days. SSB 
curves for Subject 1 and Subject 2 are A and B, respectively. IPOH curves for Subject 1 
and Subject 2 are C and D, respectively. Bacterial universal primer Bu10 was used in this 
qPCR.  Each melt curve on the graph represents the aliquot taken and lysed at the specific 
time period, the number corresponds to the time in days. The sample dilution used in this 
qPCR reaction for SSB was 10-1 dilution and pin replication dilution for IPOH. Day 21 
samples for both subjects from SSB and day 5 samples from Subject 2 from IPOH were 
excluded from analysis due to contamination in its original sample. 
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The melt curve results from the BuITS bacterial universal primer run determined which 
storage buffer was going to be used in the study. Trial storage buffer SSB, shown in Figure 3, 
gave very consistent melt peaks with Subject 1 (Figure 3A), providing evidence that there were 
no changes in the dominant species across this samples time in the buffer. Subject 2, Figure 3B, 
may look deceiving, however, all of the samples have two distinct matching melt peaks, showing 
relative consistency. The average Cq values for each of the subjects are 21.7 ± 1.18 and 19.9 ± 
1.00, respectively. These values are below 24, indicating that there were high titers of bacteria in 
these samples. Unfortunately, IPOH melt peaks data was rejected because they failed for an 
unknown reason; the DNA from the preps were previously shown to be good with the Bu10 
primer.   
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3.1.4 Species DNA Extraction more efficient with SSB/FLB than commercial FastDNA™ 
Kit 
SSB/FLB and FastDNA™ KIT extraction method extraction efficiency’s across 10 
different species were compared using a spectrophotometer, and universal primers (Bu10 and 
BuITS) and an inhibitory primer (DR3) in QPCR. The OD readings of the samples in the 
spectrophotometer, shown in Table 6, were used to verify that the samples had approximately the 
same number of cells. The OD readings combined had an average of 0.079 ± 0.0043, and only 3 
samples (E.coli, L. crispatus, and L. gasseri) were outside the standard deviation (0.075 - 0.083). 
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Figure 3. BuITS melt curves for cells lysed from SSB across 28 days for Subject 1 (A) and 
Subject 2 (B). Bacterial universal primer BuITS was used in this qPCR. Each melt curve on the 
graph represents the aliquot taken and lysed at the specific time period, the number corresponds 
to the time in days. The sample dilution used in this qPCR reaction for SSB was 10-1 dilution 
and pin replication dilution for IPOH. Day 21 samples for both subjects from SSB were 
excluded from analysis due to contamination in its original sample. Curves from cells stored in 
IPOH were rejected on the basis of qPCR quality, not a reflection of the storage. 
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The samples were also tested for inhibition to make sure that this was not a problem in the 
analysis. There was little to no inhibition in the species samples what were stored and extracted 
with SSB/FLB. All were well below 0.15 except Lactobacillus jensenii, which is outside two 
standard deviations (slightly inhibited). Lactobacillus jensenii is also outside two standard 
deviation for FastDNA™ samples (slightly inhibited). The bacterial universal primer also 
confirms that the Lactobacillus jensenii did show this slight inhibition of molecules. 
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Table 5. Information about the 10 species compared in the extraction efficiency using 
SSB/FLB and FastDNA™ Kit. 
Species Strain 
Stock 
Origin 
OD 
Read 
FastDNA 
Molec/ 
mL 
SSB/FLB 
Molec/ 
mL 
SSB/FLB: 
FastDNA 
Escherichia 
coli 
XL1-
Blue* 
frozen 
cells 
0.087 6.0E+08 6.8E+09 11 
Enterococcus 
faecalis 
RK22*** 
freshly 
grown 
agar cells 
0.079 3.4E+07 1.1E+09 32 
Lactobacillus 
crispatus 
HM-
370** 
freshly 
grown 
broth 
cells 
0.074 1.8E+08 1.9E+09 11 
Lactobacillus 
gasseri 
HM-
642** 
freshly 
grown 
broth 
cells 
0.084 1.8E+07 4.9E+09 272 
Lactobacillus 
jensenii 
HM-
646** 
freshly 
grown 
broth 
cells 
0.078 5.6E+08 2.0E+09 4 
Streptococcus 
agalactiae 
31*** 
frozen 
cells 
0.075 6.0E+06 1.9E+08 32 
Streptococcus 
cristatus 
HM-
163** 
frozen 
cells 
0.075 1.3E+06 2.2E+08 169 
Streptococcus 
downei 
HM-
475** 
frozen 
cells 
0.079 1.3E+06 1.3E+07 10 
Streptococcus 
mitis 
HM-
262** 
frozen 
cells 
0.076 6.0E+06 1.6E+09 267 
Streptococcus 
vestibularis 
HM-
561** 
frozen 
cells 
0.082 1.7E+04 1.7E+08 10000 
*Agilent Technologies, Inc (CA) 
**BEI Resources, NIAID, NIH as part of the Human Microbiome Project (VA) 
***Lab strain, identified by 16s Sequencing 
Molecules/mL were calculated from the qPCR with the 16s bacterial universal primer Bu10 
and dCq values were from qPCR with the inhibitor primer. 0.5 µL of undiluted FastDNA 
and 10-1 diluted SSB/FLB samples were used for both primers. 
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The qPCR using the universal primer Bu10 comparing the two methods, shown in Table 
6 and presented in Figure 4, gave some interesting results. The SSB/FLB method was more 
efficient at extracting amplifiable DNA than the FastDNA™ Kit. On average the SSB/FLB 
method extracted 8.8 ± 0.8 molecules/mL sample (log) for the 10 species test, whereas 
FastDNA™ only extracted 7.1 ± 1.4 molecules/mL sample (log). The FastDNA™ Kit results 
support the theory that some commercial DNA extraction methods do not extract Streptococcus 
species well, and in this case the small titer of S. vestibularis extracted was not recognizable by 
qPCR. FastDNA™ is appropriate for extracting species other than Streptococcus, but SSB/FLB 
is a better solution across all species tested and has 10-100 times more molecules of DNA from 
most of the species tested.  
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3.1.5 Bu10 and BuITS Combined Give Unique Species Melt Temperatures 
The bacterial universal primers melting temperatures can be used to decipher between 
various bacterial species. Figure 5 is a digital representation of the melting temperatures of both 
universal bacterial primers. Together they can help us distinguish between known species. There 
is not enough variation between the Bu10 single melt temperatures. However, combined with the 
multiple temperatures given from the BuITS primer it gives a unique fingerprint that reflects 
dominant species in the sample.  
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Figure 4. Comparison of FastDNA™ Kit to SSB/FLB across 10 species. (A) Ratio of 
SSB/FLB to Fast DNA extraction methods. Data presented is from 16s bacterial universal 
primer Bu10 qPCR using undiluted FastDNA™ and 10-1 diluted SSB/FLB samples. The 
SSB/FLB samples molecules/reaction was converted to undiluted samples for comparison 
against FastDNA™. (B) Log of molecules/reaction for species extracted using SSB/FLB. The 
values used in this figure are the converted undiluted SSB/FLB Bu10 data.  
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Using the known sequenced or BEI species’ melting temperatures, whether it is universal 
or one of the branch inclusive primers, to help ID prevalent species in the saliva samples is one 
of the key analysis methods. However, only the SSB/FLB identified species melting 
temperatures can be used when identifying SSB/FLB saliva samples. This is because the melting 
temperature is different between SSB/FLB and FLB only by an average standard deviation of ± 
0.72 °C, seen Figure 6 (below). The FLB only cells were processed directly from frozen BEI 
(BEI Resources, NIAID, NIH as part of the Human Microbiome Project [VA]) stocks into FLB. 
The SSB/FLB samples were stored in SSB from frozen BEI stocks then processed with FLB 
(detailed process was already mentioned). This large shift causes concern that species will not be 
identified correctly, if any FLB only samples were used for standards. Therefore, only sequenced 
or known samples that were processed with SSB/FLB will be used to identify the unknown melt 
temperatures. 
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3.2 Contamination control results 
3.2.1 No Saliva Storage Buffer Contaminants  
The distribution of 4 mL of SSB buffer into the 15 mL tubes for morning saliva samples 
could induce contamination to the samples if not done properly. A total of 6 plates were tested, 3 
of each type using 3 different tubes of SSB incubated for more than 30 days, from the same lot as 
used for study patients. There was no growth on any of the plates. 
3.2.2 No DNA Extraction Contaminants 
The process of extracting DNA from saliva that was stored in the SSB buffer for 30 days 
could have induced contamination to the samples. All samples showed no inhibition of a spiked 
template, with an average of 0.09 ± 0.07 dCq relative to template alone. Two samples had 
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positive melt peaks at 87°C with the bacterial 16s universal primer, however these samples had 
very low titers of 19.3 and 14.7 molecules/reaction similar to those of the negative wells in the 
qPCR. Also the duplicates of these samples did not show melt peaks and were also very low in 
titer (1.50 and 4.37 molecules per reaction). Therefore, no high titer contaminants were present 
to alter the titers of saliva samples. 
3.2.3 Puccinia striiformis f. sp. tritici is an Air Contaminant 
The universal primers are very sensitive and can amplify possible air contaminants. 
Working in a lab where bacterial and fungal species are constantly being streaked for growth, 
there can be a lot of airborne species, especially fungal and mold. Two colonies grew. FLB’s of 
the colonies were made and tested with the fungal universal primer and were prepped to be sent 
out for sequencing. The FLB’s of the two colonies had two identical melt peaks with averages 
and standard deviations of 89.09 °C ± 0.07 °C and 85.36 °C ± 0.07 °C. Sequences came back as 
Puccinia striiformis f. sp. tritici and none of the saliva samples tested have these melt 
temperatures. Therefore it is unlikely that species detected in samples derive from the 
environment in which the samples were processed. 
3.2.4 DNA prepared by SSB/FLB DNA was not degraded during the study interval 
Each plate of samples did endure multiple freeze thaws in order to complete different 
primer qPCR’s. The concern is that these multiple freeze thaws would cause DNA template 
degradation. I compared results from 108 samples assayed at the beginning of the study with the 
same samples re-assayed 84 days later at the end of the study, after approximately 13 freeze-
thaws (Figure 7). A Wilcoxon matched-pairs signed rank test had a P Value of 0.4298 and is 
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considered not significantly different. Therefore, there was no significant DNA template/sample 
degradation. 
 
 
 
3.3 Molecular Characterization 
3.3.1 qPCR Primers Biorad Cq Call Based on Highest %E 
All three methods of calculating Cq values showed impressively low average standard 
deviations among all serial dilutions (Figure 8).  Therefore it is important to compare the percent 
efficiencies to choose the best call. In this case with the Bu10 primer the Regression Cq call is 
shown to be the highest, with an efficiency of 94.1%. Single Threshold-Custom and Single 
Threshold-Auto follow with 82.8% and 82.7% respectively. For all other primers, the percent 
efficiencies given by the CFX will be compared for each Cq call type for several runs and the 
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Figure 8. The average standard slopes for each of the three methods of determining Cq 
values in the CFX Biorad program. The Bu10 primer standard was compiled from 34 runs 
and graph equations and percent efficiencies were calculated using excel; no outliers were 
excluded.  
 
 
highest % efficiencies will be used. Again, all of the primers used in this study can be found in 
Appendix D, along with additional information regarding primer make-up and qPCR. The qPCR 
run-to-run variation for each primer can be seen in the average and standard deviations of the 
percent effiencies, Appendix D.  
 
 
3.3.2 Oral Bactria and Fungal Library Composition 
All of the information on the 364 saliva cells species that were grown for the oral lab cell 
library can be found in Appendix C. A total of 11 volunteers’ saliva was used to create this 
library and 30.6% (110/364) of the oral cell library has been identified through sequencing. The 
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library, chosen from different combined Bu10 and BuITS representative melting temperatures, 
consists of 3 major phyla: Firmicute, Actinobacteria, and Proteobacteria. Figure 9 contains the 
break-down of the contents of the oral library based on the sequencing results. 70% of the 
species come from the families: Lactobacillaeae, Actinobacteridae, and Streptococcus. The oral 
cell library consists of 230, or 63.2%, xerostomia saliva cells and 134, or 36.8%, healthy saliva 
cells. From the identified saliva cultures, 51.8% were from xerostomia patients.  
Species identified only found in these volunteers were (prevalence in parenthesis): 
Lactobacillus fermentum (3), Rothia mucilaginosa (4), Staphylococcus epidermidis (3), and 
Streptococcus salivarius (5). This data will be combined with all sequencing data and further 
analyzed for differences among the groups in the next section, Section 3.3.3. 
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Figure 9. Oral cultured library composition based on sequencing. (A) Phyla distribution of 
oral cell library. (B) Family distribution of oral cell library. (C) Species of oral cell library 
with prevalence, within 97 % identity over 97% read length.  The different shades of colors 
in the figures represent the phyla of microbes: green (Actinobacteria), red (Firmicutes), blue 
(Proteobacteria), and black (other). All cells’ DNA sequenced were from 16s bacterial 
universal primer qPCR. 
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3.3.3 Composition of Sequenced qPCR Samples 
A total of 401 DNAs amplified with a variety of primers (Table 6) were sequenced. Only 
244 (60.8%) of the amplicons (from 12 primers) that returned readable sequences had species 
matches with 95% coverage and identity. Any primers that did not return with sequences 
matched with at least 95% coverage and identity and/or a majority of the amplified samples 
matched species outside its target were rejected. Therefore, two primers were rejected, 
ChlamITS (Chlamydia) and MycoUreaITS (Mycoplasmatales). All information on the amplicons 
sequenced, including DNA sequence and melting temperatures, can be found in Appendix E. 157 
(39.2%) were mixed template reads, which could be a result from codominant species. Overall,  
49.2% of the sequenced amplicons were from the study salvia samples, 46.6% were from the 
Oral Cell Library (Section 3.3.2), and the remaining 4.2% of the matched sequences came from 
other previous experiments from Chapter 2, such as the air contamination experiment. The saliva 
samples that matched species sequences came from 14 xerostomia volunteers, 15 control 
volunteers, and 8 nightly routine volunteers.  
A total of 68 species were identified across all the matched sequences. The distribution of 
these species from each target primer is presented in Table 7 A & B. Only the Staphylococcus 
primer amplified a sequence outside of its target branch; it had two reads with 99% coverage and 
97-99% identities for Streptococcus pneumonia, likely resulting from the close relationship of 
the two targets and the dominant titers of Streptococcus. The melting temperatures for each 
species matched, listed in Appendix E, suggests what the dominant species of each sample is in 
the study. However, it is important to note that the melting temperature for each species is primer 
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specific. Further analysis on which species are more dominant in each saliva sample will be done 
in Sections 3.4 and 3.5. 
Table 6. Breakdown of sequenced matches 
Primer Target Primer 
Primer 
Name 
Total 
Samples 
Total 
Target 
Total 
Non-
target 
 Mixed 
template 
reads* 
Percent 
Target 
Actinobacteridae ActinoR3 Actin-R  16 11 0 5 100 
Betaproteobacteria BProt16SITS BPro-F 3 0 0 3 100 
Bacterial Broad-spectrum 
Bu4L 
Bu4LC 
Bu4L2 
Bu4L3 
Bact-F 157 129 0 28 100 
Enterococcaceae EntcR Ent-R  2 1 0 1 100 
Fungal Broad-spectrum RT2 Fung-R  74 49 0 25 100 
Fusobacterium Fuso-R6 Fuso-R  8 7 0 1 100 
Lachnospiraceae uc & 
incertae sedis, Clostridium 
IVa, Roseburia 
Lachno-R3 Lach-R  19 6 0 13 100 
Lactobacillaceae 
LB16SITSfvr 
LB16SITSvsp 
LB16SITSj 
LB16SITSsc 
Lacto-F  44 13 0 31 100 
Megasphaera/Dialister/ 
Veillonella 
MegaR869 Mega-R  4 4 0 0 100 
Bacteroidaceae/ uc 
Prevotellaceae 
OidiesITSFa 
OidiesITSFb 
OidiesITSFc 
Oides-F 16 9 0 7 100 
Staphylococcus Staph16sITS Staph-R  44 14 2 30 88 
Streptococcus Strep16SITSL Strep-R  12 1 0 11 100 
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Table 7 A. Sequence Read Summary 
A Target Primer Name 
Bacterial species detected B
ac
t-
F
 
A
ct
in
-R
  
E
n
t-
R
  
F
u
so
-R
  
L
ac
h
-R
  
L
ac
to
-F
  
M
eg
a-
R
  
O
id
es
-F
 
S
ta
p
h
-R
  
S
tr
ep
-R
  
F
u
n
g
-R
  
T
o
ta
l 
Actinomyces graevenitzii 
 
2 
         
2 
Actinomyces odontolyticus 
 
1 
         
1 
Actinomyces viscosus 
 
3 
         
3 
Atopobium sp. 
 
2 
         
2 
Rothia dentocariosa 8 2 
         
10 
Rothia mucilaginosa 4 1 
         
5 
Rothia sp. 10 
          
10 
Gordonia sp. 5 
          
5 
Gemella haemolysans 5 
 
1 
        
6 
Gemella sanguinis 3 
          
3 
Gemella sp. 1 
          
1 
Fusobacterium nucleatum subsp. 
Animalis 
   
1 
       
1 
Fusobacterium periodonticum 
   
6 
       
6 
Oribacterium sinus 
    
3 
      
3 
Stomatobaculum longum 
    
3 
      
3 
Abiotrophia defectiva 
     
10 
     
10 
Lactobacillus casei 4 
          
4 
Lactobacillus fermentum 3 
    
2 
     
5 
Lactobacillus gasseri 5 
          
5 
Lactobacillus paracasei 2 
          
2 
Lactobacillus rhamnosus 8 
          
8 
Lactobacillus rossiae 1 
          
1 
Lactobacillus sp. 6 
          
6 
Veillonella dispar       4     4 
Prevotella melaninogenica        7    7 
Prevotella veroralis        2    2 
Staphylococcus aureus 1        3   4 
Staphylococcus epidermidis 3        9   12 
Staphylococcus aureus subsp. Aureus 5           5 
Staphylococcus caprae 2           2 
Staphylococcus sp. 3           3 
Neisseria flava 4           4 
Neisseria perflava 1           1 
Neisseria sp. 2           2 
Neisseria subflava 2           2 
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Table 7 B. Sequence Read Summary 
B Target 
Bacterial species detected B
ac
t-
F
 
A
ct
in
-R
  
E
n
t-
R
  
F
u
so
-R
  
L
ac
h
-R
  
L
ac
to
-F
  
M
eg
a-
R
  
O
id
es
-F
 
S
ta
p
h
-R
  
S
tr
ep
-R
  
F
u
n
g
-R
  
T
o
ta
l 
Streptococcus pneumoniae 
        
2 
  
2 
Streptococcus anginosus 1 
          
1 
Streptococcus australis 2 
          
2 
Streptococcus genomosp. 2 
          
2 
Streptococcus mitis 5 
          
5 
Streptococcus mutans 1 
          
1 
Streptococcus salivarius 13 
        
1 
 
14 
Streptococcus salivarius subsp. Null 4 
          
4 
Streptococcus sp. 6 
          
6 
Streptococcus thermophilus 1 
          
1 
Haemophilus parainfluenzae 1 
          
1 
Haemophilus sp. 2 
          
2 
human oral bacterium 1 
          
1 
uncultured bacterium 2 
          
2 
Fungal species detected 
Aureobasidium proteae 
          
1 1 
Aureobasidium pullulans 
          
1 1 
Candida albicans 
          
17 17 
Candida dubliniensis 
          
2 2 
Candida glabrata 
          
1 1 
Candida parapsilosis 
          
2 2 
Candida tropicalis 
          
1 1 
Cladosporium perangustum 
          
1 1 
Cryptococcus sp. 
          
1 1 
Malassezia restricta 
          
4 4 
Metarhizium brunneum 
          
1 1 
Puccinia striiformis f. sp. Tritici 
          
3 3 
Rhodotorula mucilaginosa 
          
1 1 
Saccharomyces cerevisiae 
          
1 1 
Uncultured basidiomycete ITS region 
          
4 4 
Uncultured compost fungus 18S rRNA gene 
          
1 1 
Uncultured eukaryote clone 
          
1 1 
Uncultured fungus clone 
          
6 6 
Uncultured Glomus clone 
          
1 1 
Total 129 11 1 7 6 12 4 9 14 1 50 244 
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3.4 Xerostomia vs. Control Study Arm 
3.4.1 Volunteer Enrollment 
Each volunteer enrolled filled out a dental health questionnaire, the blank questionnaire can be 
found in Appendix A, each enrolled volunteers answers are presented in Appendix F. A total of 
36 volunteers were enrolled in this study, 
18 xerostomia and 18 healthy controls. A 
detailed characterization of the 
xerostomia and control volunteers is 
found in Table 8.  
Comparing the volunteer’s saliva 
tests, in the groups that they enrolled as 
(control or xerostomia), can be seen in 
Figure 10. There was no significant 
difference between controls or 
xerostomias’ saliva pH, due to definite 
overlaps in these groups. However, even 
though there are several overlaps also 
seen between the groups in their 
unstimulated and stimulated saliva flow 
tests, both of their group means were 
significantly different. Mann Whitney t-
Table 8. Characterization of xerostomia and control 
volunteers 
  Xerostomia Control 
Total 
Enrolled 18 18 
Male 4 10 
Female 14 8 
White 16 16 
Black 1 1 
Asian 1 1 
Diagnosed 
xerostomia 4 0 
Symptomatic 
xerostomia 14 0 
Periodontal or 
Gingivitis 3 2 
Wear Dentures 2 3 
Cosmetic 
Dentistry 4 1 
Average 
Age (years) 54.3 ± 22.9 55.7 ± 23.8 
Cavities (#) 10.3 ± 8.0  5.8 ± 5.5 
Root canals (#) 0.9  ± 1.3  0.8 ± 0.9 
Crowns (#) 2.7 ± 2.8 1.4 ± 2.4 
pH 5.6 ± 0.5 5.9 ± 0.4 
unstimulated 
(mL) 0.6 ± 0.4 1.4  ± 0.4 
stimulated 
(mL) 3.4 ± 1.7 6.4 ± 2.5 
flow sum (mL) 4.0 ± 1.9 7.9 ± 2.5 
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tests gave a P value of <0.0001 for unstimulated and a P value 0.0002 for stimulated flow rates. 
By combining the unstimulated value with the stimulated value the overlap between the two 
groups was minimized but not eliminated, and their new means were significantly different with 
a P value <0.0001 from a Mann Whitney t-test. However, because of the overlap between these 
groups, one cannot use this test to solely determine whether they are xerostomic or not. 
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Figure 10.  Saliva tests’ results. (A) pH of enrolled control vs. xerostomia volunteers. (B) 
Unstimulated saliva flow (mL) of enrolled control vs. xerostomia volunteers. (C) Stimulated 
saliva flow (mL) of enrolled control vs. xerostomia volunteers.  (D) Saliva flow sum of 
enrolled control vs. xerostomia volunteers.  
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3.4.2 Xerostomia patients’ saliva samples do not have higher bacterial loads than controls 
The total bacterial titers (16s) for each volunteer varied up to 100 fold from one day to 
the next, although the 3 sample limit did not allow a determination of whether these differences 
were significant  (1-way ANOVA Dunn’s multiple comparisons test, P value >0.9). The 
variations in the total fungi titers also failed the ANOVA test for significance. However, a 1-way 
ANOVA test on the volunteer’s enrolled in the xerostomia vs. control study gave a P value of 
<0.0001, indicating that the means vary significantly between individuals. Figure 11 A. presents 
the total bacterial titers (16s) in log form for each individual’s three samples given. These titers 
are at least partially confounded by variations in spit volumes, which ranged from 0.25 mL to 3 
mL. 
Individual differences in melting temperatures (dominant species) were found when 
comparing samples from each individual sample, (Figure 11 B). This reflects daily changes in 
which species are dominant. There is less deviation from day to day within individuals (average 
standard deviation = 0.10 °C) than the deviation among all samples (standard deviation = 0.23 
°C). These data also indicate that healthy oral samples almost always have several co-dominant 
species, each contributing to the Tm values. Diagrams for each primer are found in Appendix F. 
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Figure 11. Bacterial titers from xerostomia and control three sequential samples. Total titers 
are found in (A) and melting temperatures can be found in (B). Data was generated from the 
qPCR run using the bacterial universal primer (16s).  
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3.4.3 Oral microbial composition for each volunteer 
The composition of dominant species for each volunteer varies, but there are two phyla 
that outnumber the others and compete for dominance: Streptococcus and Megasphera/ 
Dialister/ Veillonella (Fig. 12; Appendix L). The 2-way ANOVA test on the volunteer’s average 
titers for each primer showed no significant difference of any individual compared to an overall 
average titer per target, nor between average titers per target between control and xerostomic 
groups. At the level of resolution depicted in Figure 12, there is not a dramatic difference in 
magnitudes of titer changes between controls versus xerostomic groups. 
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Figure 12. Percent composition of oral microbes for xerostomia and control volunteers. The 
percentages are based on titers from each primer per individual. Each individuals’ three 
samples were averaged.  
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3.4.4 Dominant populations of xerostomia and controls 
Titer data was analyzed by using a Mann Whitney t-test on log molecules per reaction 
values for each volunteer’s sample. Because there was no tight control of saliva volumes, I 
compared titers of subgroups as percentages of total titers of the sample; the latter was 
determined both by Bu10 titers and by summing titers from all PB qPCR reactions. Even with 
overlap between the groups, there were significant decreases in a subset of bacterial branches’ 
average titers in xerostomia as compared to controls, most dramatically 5 and 18 fold reductions 
in Lachnospiracea and in Bacteroidaceae, respectively (Fig. 13).  Xerostomia samples were 
significantly lower in microbial populations of Lactobacillaceae (1.3 x 104 in controls, 6.67 x 
103 in xerostomia, P = 0.027), Betaproteobacteria (2.26 x 104 in controls, 8.18 x 103  in 
xerostomia, P = 0.014), Megasphaera/Dialister/Veillonella (8.5 x 105 in controls, 4.82 x 105 in 
xerostomia, P = 0.0068), Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (1.75 x 103 
in controls, 3.76 x 102 in xerostomia, P = 0.0003), and Bacteroidaceae/ uc Prevotellaceae (4.05 
x 104  in controls, 2.31 x 103 in xerostomia, P = <0.0001). All of the figures for every primer of 
control versus xerostomia can be found in figures in Appendix G.  
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Xerostomia patient samples were depleted of several species relative to controls, as 
indicated by missing or less prevalent species with BuITS or more specific primers (Figure #...). 
Samples species were analyzed by uncorrected multiple comparisons Fisher’s LSD ordinary two-
way ANOVA and significant species differences were seen in the several primers (Appendix H). 
BuITS detected three species that were significantly lower in prevalence in xerostomia versus 
control samples. They were BuITS-81.2 (10 in controls, 3 in xerostomia, P = 0.031), BuITS-85.6 
(9 in controls, 2 in xerostomia, P = 0.031), and BuITS-88 (15 in controls, 5 in xerostomia, P = 
0.0029). These species would reflect dominant bacterial species, either Streptococcus or 
Megasphaera/Dialister/ Veillonella, therefore these could be: Streptococcus sp., Streptococcus 
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Figure 13. Average titers (log) significantly different for xerostomia and control volunteers. 
The averages are based on titers from each primer per individual in each group. LBITS= 
Lactobacillaceae, BProITS= Betaproteobacteria, Mega= Megasphaera/Dialister/Veillonella, 
Lachno= Lachnospiraceae/incertae sedis/clostridum Iva/Roseburia, and OidesITS= 
Bacteroidaceae/un Prevotellaceae  
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mitis, Streptococcus salivarius subsp. Null, and Streptococcus mutans. Xerostomia also had a 
significantly lower amount (17 in controls, 8 in xerostomia, P = 0.047) of Lachnospiraceae/ 
incertae sedis/ clostridum IVa/ Roseburia with the melt temperature of Lachno-86.4, based on 
sequencing results this may be Oribacterium sinus.  
Other branches that had a significantly lower prevalence in xerostomia were 
Staphylococcus and Bacteroidaceae/ uc Prevotellaceae. Staphylococcus was also found to be 
significantly lower (22 in controls, 14 in xerostomia, and 21 in controls, 11 in xerostomia, P = 
0.020 and 0.0048) in species StaphITS-80.4 and StaphITS-80.6. Certain species of 
Bacteroidaceae/ uc Prevotellaceae were found to be less prevalent in xerostomia. Xerostomia 
had a significantly lower amount (15 in controls, 9 in xerostomia, P = 0.032) of OidesITS-81.6. 
Bacteroidaceae/ uc Prevotellaceae also found to be significantly lower (8 in controls, 1 in 
xerostomia, P = 0.013) in OidesITS-90, and sequencing results suggests this may be Prevotella 
melaninogenica. 
Some branches had a significant increase in prevalence for one species but a significant 
decrease in another for xerostomia, based off of the control. For example, Lactobacillaceae 
primers detected lower prevalence (16 in controls, 8 in xerostomia, P = 0.0043) of LBITS-87.6, 
likely Lactobacillus fermentum, possibly Abiotrophia defectiva. In contrast there was higher 
prevalence (2 in controls, 8 in xerostomia, P = 0.027) of LBITS-90.2. There was lower 
prevalence of Betaproteobacteria among xerostomia patients (10 in controls, 1 in xerostomia, P 
= 0.0038) of BProITS-86, but higher prevalence (3 in controls, 12 in xerostomia, P = 0.0038) of 
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BProITS-84. These data indicate compositional changes in the two patient groups that warrant 
further study by NGS. 
Certain species of fungi were found to be more prevalent among xerostomia patients. 
More prevalent species among xerostomia included Fungi-84.4 (6 in controls, 15 in xerostomia, 
P = 0.029) likely to be Candida albicans, Fungi-84.8 (9 in controls, 23 in xerostomia, P = 
0.0011) and Fungi-86.6 (18 in controls, 32 in xerostomia, P = 0.0011), likely Saccharomyces 
cerevisiae and Candida albicans. In contrast, no melt/species of fungi was significantly more 
prevalent in controls than in xerostomia. All of the significant differences in the species noted in 
the paragraphs above are depicted Figure 14.  
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Figure 14. Prevalence of species significantly different for xerostomia and control 
volunteers. The averages are based on titers from each primer per individual in each group.  
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3.4.5 Dominant populations of high flow versus low flow 
Although significant differences 
between xerostomia and controls were 
seen for some bacterial groups, others 
may have been overlooked due to the 
imperfect grouping of the groups by 
self-reported symptoms. Therefore all 
volunteers were separated into two 
groups based on their saliva flow sum 
values to see if there were any 
significant differences between 
microbial populations. Volunteers that 
had a saliva flow sum <6.0 were put in 
“low flow” (20 volunteers) and 
volunteers with a saliva flow sum of 6.0 
or greater were grouped into “high 
flow” (16 volunteers), based on 
observed gaps in the distribution. This 
criteria moved three xerostomia individuals into the high flow group and five controls into the 
low flow group. Table 9 gives a characterization of the two groups. 
Table 9. Characterization of low flow and high flow sum 
volunteers 
  Low Flow High Flow 
Total 
Enrolled 20 16 
Male 5 9 
Female 15 7 
White 18 14 
Black 1 1 
Asian 1 1 
Diagnosed 
xerostomia 3 1 
Symptomatic 
xerostomia 12 2 
Periodontal or 
Gingivitis 4 1 
Wear Dentures 3 2 
Cosmetic 
Dentistry 5 0 
Average 
Age (years) 51.1 ± 24.1 59.8 ± 21.4 
Cavities (#) 9.3 ± 7.5 6.8 ± 6.6 
Root canals (#) 0.9  ± 1.3  0.8 ± 0.9 
Crowns (#) 2.3 ± 2.7 1.8 ± 2.6 
pH 5.7 ± 0.5 5.8 ± 0.5 
unstimulated 
(mL) 0.7 ± 0.5 1.4  ± 0.4 
stimulated 
(mL) 3.1 ± 1.2 7.2 ± 2.0 
flow sum (mL) 3.9 ± 1.5 8.6 ± 2.1 
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Titer data was analyzed by using a Mann Whitney t-test. Low flow volunteers were 
significantly lower in titer averages, as compared to high flow (control), most dramatically a 20 
fold lower average titer for Bacteroidaceae/ uc Prevotellaceae (Figure 15). The following target 
groups were lower: Betaproteobacteria (low flow 9.58 x 103, high flow 2.10 x 104, P = 0.0433), 
Megasphaera/Dialister/Veillonella (low flow 4.80 x 105, high flow 9.20 x 105, P = 0.012), 
Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (low flow 4.36 x 102, high flow 1.76 
x 103, P = 0.0053), Fusobacterium (low flow 2.32 x 104, high flow 6.85 x 104, P = 0.0047) and 
Bacteroidaceae/ uc Prevotellaceae (low flow 2.30 x 103, high flow 5.83 x 104, P = 0.0003). All 
of these differences in average titers per target can be found in figures in Appendix G. 
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Figure 15. Average titers (log) significantly different for low flow and high flow 
volunteers. The averages are based on titers from each primer per individual in each 
group. BProITS= Betaproteobacteria, Mega= Megasphaera/Dialister/Veillonella, 
Lachno= Lachnospiraceae/incertae sedis/clostridum Iva/Roseburia, Fuso= 
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 BuITS melt analysis of low versus high flow groups showed two species that differed in 
prevalence. Melting temperature prevalence data was analyzed by multiple comparisons 
uncorrected Fisher’s LSD ordinary two-way ANOVA and the significant species differences 
were seen in the several primers (Appendix H). The first species BuITS-88 was found to be 
significantly lower (low flow 2, high flow 18, P = 0.0022) in low saliva flow, but the second 
species BuITS-88.4, was found to be significantly higher (low flow 23, high flow 9, P = 0.0066) 
in low saliva flow. These temperatures would reflect dominant bacterial species, either 
Streptococcus or Megasphaera/Dialister/ Veillonella, therefore these temperatures could be: 
Streptococcus sp., Streptococcus salivarius subsp. Null, and Streptococcus mutans. 
However, in the fungal universal primer ITS, all species were found to be significantly 
higher in low flow. These are Fungi-84.4 (low flow 17, high flow 4, P = 0.0014; Candida 
albicans, Candida tropicalis) Fungi-84.8 (low flow 22, high flow 10, P = 0.0029; Candida 
albicans, Saccharomyces cerevisiae, Aureobasidium proteae), Fungi-86.4 (low flow 13, high 
flow 5, P = 0.040; Candida albicans, or Uncultured basidiomycete), and Fungi-86.6 (low flow 
29, high flow 21, P = 0.040; Candida albicans, Malassezia restricta). Another branch primers 
that had species prevalence significantly higher in low flow was Lactobacillaceae. 
Lactobacillaceae were found to be more prevalent at LBITS-87.8 (low flow 12, high flow 6, P = 
0.035; Abiotrophia defectiva) and LBITS-90.2 (low flow 9, high flow 1, P = 0.0063).  
Betaproteobacteria and Staphylococcus groups showed a significant increase in 
prevalence for one species but a significant decrease in another for low flow compared to high 
flow. Low saliva flow was found to have significantly higher in prevalence (low flow 16, high 
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flow 5, P = 0.0024) of BProITS-83.6 for Betaproteobacteria, but significantly lower prevalence 
(low flow 1, high flow 10, P = 0.011) in BProITS-86.0. Among Staphylococcus spp., low flow 
was significantly lower (low flow 2, high flow 6, P = 0.039) in StaphITS-86.6 (Staphylococcus 
epidermidis), but significantly higher (low flow 16, high flow 12, P = 0.039) in StaphITS-87.0 
(Staphylococcus aureus or Streptococcus pneumonia). Among Bacteroidaceae/ uc 
Prevotellaceae, species OidesITS-88.6 (Prevotella melaninogenica) was less prevalent in low 
flow as compared to high flow (low flow 0, high flow 11, P = 0.0008). Figure 16 shows these 
significant differences between the species in these groups. 
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Figure 16. Prevalence of species significantly different for low flow and high flow 
volunteers. The averages are based on titers from each primer per individual in each group. 
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The analysis of low flow versus high flow groups was more sensitive for detected 
differences in prevalence than was the xerostomic versus healthy grouping. Both showed 
compositional differences that warrant further analysis by NGS. 
3.4.6 Dominant populations of control versus medication 
The volunteers of the xerostomia and control study were separated into two groups based 
on their questionnaire answers 
for medication to distinguish if 
there were any significant 
differences between microbial 
populations. The first group 
consisted of volunteers that 
currently took medications that 
cause dry mouth (xerostomia) 
and were named the 
“medication-induced 
xerostomia” or MIX group. 
The second group consisted of 
age-matched volunteers that 
did not take medications that 
cause dry mouth and were 
named “controls”. 
Table 10. Characterization of MIX vs. control volunteers 
  MIX Control 
Total 
Enrolled 11 11 
Male 7 5 
Female 4 6 
White 10 10 
Black 1 0 
Asian 0 1 
Diagnosed xerostomia 2 0 
Symptomatic xerostomia 6 0 
Periodontal or 
Givingivitis 0 1 
Wear Dentures 1 2 
Cosmetic Dentistry 2 1 
Average 
Age (years) 57.1 ± 23.8 57.5 ± 24.7 
Cavities (#) 9.2 ± 7.1 6.4 ± 6.7 
Root canals (#) 0.9  ± 1.2  0.7 ± 0.8 
Crowns (#) 1.9 ± 2.0 1.8 ± 2.9 
pH 5.5 ± 0.5 6.0 ± 0.4 
unstimulated (mL) 0.8 ± 0.5 1.6  ± 0.3 
stimulated (mL) 4.2 ± 1.5 6.5 ± 2.5 
flow sum (mL) 5.1 ± 1.8 8.0 ± 2.6 
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Characterization of the volunteers in each of these groups can be found in Table 10. 
Titer data was analyzed by using a Mann Whitney t-test. Significant decreases in titer 
averages in MIX volunteers were seen in these three primers: Bacteroidaceae/ uc Prevotellaceae 
(MIX 5.43 x 103, control 3.90 x 104, P = 0.0368), Betaproteobacteria (MIX 6.77 x 103, control 
4.59 x 104, P = 0.0279), and Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (MIX 
5.68 x 102, control 2.21 x 103, P = 0.0159). These significant differences can be seen in Figure 
17. All of the differences from each of the primers tested can be found in figures in Appendix G.  
 
 
There were several similarities and few significant differences between the prevalence of 
the two groups’ species. Species prevalence data was analyzed by multiple comparisons 
uncorrected Fisher’s LSD ordinary two-way ANOVA and the significant species differences 
were seen in the several primers (Appendix H). The bacterial universal primer ITS, was shown to 
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Figure 17. Average titers (log) significantly different for xerostomia and control 
volunteers. The averages are based on titers from each primer per individual in each 
group. BProITS= Betaproteobacteria, Lachno= Lachnospiraceae/incertae 
sedis/clostridum Iva/Roseburia, and OidesITS= Bacteroidaceae/un Prevotellaceae  
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have three species that were significantly different between MIX and controls. The first two 
species, BuITS-81.2 and BuITS-84.6, were found to be significantly higher (MIX 7, control 3, 
and MIX 4, control 0, P = 0.042) in MIX, but the species BuITS-88, was found to be 
significantly lower (medicated 4, control 9, P= 0.012). These temperatures reflect dominant 
bacterial species in the Streptococcus or Megasphaera/Dialister/ Veillonella target group, likely 
Streptococcus sp., Streptococcus salivarius subsp. Null, or Streptococcus mutans. 
Branches that had a significant increase in prevalence for one temperature but a 
significant decrease in another temperature for MIX, compared to controls, were found in the 
fungal universal primer and Betaproteobacteria. Fungi species Fungi-84.6 (likely Cryptococcus 
sp., possibly Candida albicans) were found to be significantly reduced in MIX (MIX 5, control 
11, P= 0.048), but Fungi-86.4 (likely Candida albicans, possibly an uncultured basidiomycete) 
were significantly increased in MIX (MIX 11, control 1, P= 0.0018). Betaproteobacteria species 
BProTIS-84.0 were found to be significantly more prevalent (MIX 7, control 2, P= 0.013) in 
MIX and species BProITS-85.6 and BProITS-86.0 were found to be significantly less prevalent 
(MIX 0, control 4, and MIX 2, control 6, P= 0.043). Unfortunately, possible species for these 
temperatures were not matched with DNA sequences from RDP for this primer. 
 Lactobacillaceae species were found to be more significantly prevalent in MIX 
volunteers. LBITS-84.6 and LBITS-87.6 (Lactobacillus fermentum or Abiotrophia defectiva) 
were found only in MIX (MIX 5, control 0, and MIX 11, control 6, P= 0.043). Species for these 
temperatures did not closely match with DNA sequences from the RDP database for these 
primers. 
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Lastly, MIX volunteers were found to be significantly less prevalent in species from the 
branches of Staphylococcus and Bacteroidaceae/ uc Prevotellaceae. Staphylococcus species of 
StaphITS-80.8 (Staphylococcus epidermidis) were 10-fold more prevalent in controls (MIX 1, 
control 9, P= 0.018). Bacteroidaceae/ uc Prevotellaceae species OidesITS-81.6 were 5-fold 
more prevalent in controls (MIX 2, control 10, P= 0.0027) and OidesITS-90.0 was seen only in 
controls (MIX 0, control 6, P= 0.021, respectively) in these volunteers. 
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Figure 18. Prevalence of species significantly different for MIX and controls. The averages 
are based on titers from each primer per individual in each group.  
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3.5 Nightly Oral Hygiene Practices Arm 
3.5.1 Volunteer Enrollment 
A total of 17 volunteers, 8 males and 9 
females, were enrolled in this study with an 
age range of 18-60 years, and an average age 
of 27.1 ± 10.5 years. A detailed 
characterization of the xerostomia and control 
volunteers is found in Table 11.  
Titer data was analyzed by using a 
1way ANOVA Dunn's multiple comparisons 
test on log molecules per reaction values for 
each volunteer’s sample per nightly routine 
(Appendix J). Because there was no tight 
control of saliva volumes, I compared titers of subgroups as percentages of total titers of the 
sample. Even with overlap between the groups, there were significant decreases in many 
bacterial branches’ average titers in different nightly routines as compared to no nightly oral 
hygiene routine (none).  Nightly oral hygiene routine samples were depleted of several species 
relative to controls (none or no nightly routine), as indicated by missing or less prevalent melt 
temperatures with BuITS or more specific primers (Appendix K). Samples melting 
temperatures/species were analyzed by uncorrected multiple comparisons Fisher’s LSD ordinary 
Table 11. Characterization of nightly routine 
volunteers  
Total 
Enrolled 17 
Male 8 
Female 9 
White 14 
Black 0 
Asian 3 
Periodontal or 
Gingivitis 1 
Wear Dentures 0 
Cosmetic Dentistry 1 
Average 
Age (years) 27.1 ± 10.5 
Cavities (#) 4.5 ± 3.5 
Root canals (#) 0.4  ± 1.0 
Crowns (#) 0.2 ± 0.7 
pH 6.0 ± 0.5 
unstimulated (mL) 1.0 ± 0.5 
stimulated (mL) 6.3 ± 3.0 
flow sum (mL) 7.3 ± 3.2 
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two-way ANOVA and the significant species differences were seen in the several primers 
(Appendix K). 
Analysis in Section 3.5.2- 3.5.5 refer to titers averaged among the 17 patients. 
3.5.2 Dominant species after Listerine mouthwash 
After use of Listerine mouthwash (Fig. 19), Lactobacillaceae (1.03 x 104 in none, 4.17 x 
103 in Listerine mouthwash, P = < 0.0001) and Fusobacterium (2.99 x 104 in none, 1.79 x 104 in 
Listerine mouthwash, P = 0.01) titers were reduced about two-fold. Other average titers did not 
show significant reduction. 
  
A number of specific species, as provisionally defined by their melt temperatures, were 
reduced in prevalence after Listerine (Fig. 20). I use the nomenclature for these unnamed species 
as follows: the primer being used – melt temperature. BuITS detected seven melt temperatures 
that were significantly lower in Listerine mouthwash versus control samples: BuITS-80.4 (16 in 
controls, 2 in Listerine mouthwash, P = 0.0168), BuITS-81 (15 in controls, 2 in Listerine 
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Figure 19. Average titers (log) 
significantly different for 
Listerine mouthwash and none 
across all volunteers. The 
averages are based on titers from 
each primer per individual in each 
group. LBITS= Lactobacillaceae, 
and Fuso= Fusobacterium  
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mouthwash, P = 0.0299), BuITS-84.4 (20 in controls, 7 in Listerine mouthwash, P = 0.0299), 
BuITS-86.4 (24 in controls, 11 in Listerine mouthwash, P = 0.0299), BuITS-88 (44 in controls, 
29 in Listerine mouthwash, P = 0.0091), BuITS-88.2 (41 in controls, 17 in Listerine mouthwash, 
P = < 0.0001), and BuITS-88.4 (37 in controls, 15 in Listerine mouthwash, P = < 0.0001). 
Species Bu10-87.0 was more than two-fold less prevalent in Listerine mouthwash (58 in control, 
25 in Listerine mouthwash, P = 0.059). Fusobacterium (Fuso- 85.0, possibly Fusobacterium 
periodonticum) was also reduced in prevalence by at least two-fold (59 in controls, 25 after 
Listerine mouthwash, P = 0.001). Fuso-85.2 (possibly Fusobacterium periodonticum) was 
reduced by at least 1.6 fold with 59 in controls, 35 in Listerine mouthwash (P = 0.0229). 
Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia detected species/melts that were 
significantly lower than the control. The first, Lachno-86.4 (possibly Oribacterium sinus), was 
two- to three-fold lower, 45 in none and 23 in Listerine mouthwash (P = 0.0152). 
Lactobacillaceae detected three species/melts with significantly lower titers: LbITS-87.4, 
possibly Abiotrophia defectiva (39 in controls, 21 after Listerine mouthwash, P = 0.0009), 
LbITS-87.6 possibly Abiotrophia defectiva, 33 in controls, 21 in Listerine mouthwash (P = 
0.0429), and LbITS-87.8 possibly Abiotrophia defectiva, with 41 in controls, 16 in Listerine 
mouthwash (P = < 0.0001). One Lactobacillus species, LbITS-87.2, was 13-fold lower, but only 
after Listerine mouthwash (13 in control, 1 in Listerine mouthwash, P = 0.0429). Strep-88 was 
reduced more than two-fold (51 in controls, 18 after Listerine mouthwash, P = 0.0231). 
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3.5.3 Dominant species of Crest mouthwash 
Bacterial populations were significantly decreased after nightly use of Crest mouthwash 
in all six of the branches tested, by about 2 to 7 fold (Figure 21). This included: bacterial 16s 
(1.30 x 106 in none, 4.47 x 105 in Crest mouthwash, P = 0.0006), bacterial ITS (6.35 x 105 in 
none, 2.64 x 105 in Crest mouthwash, P = 0.0077), Lactobacillaceae (1.03 x 104 in none, 6.34 x 
103 in Crest mouthwash, P = 0.023), Streptococcus (4.37 x 105 in none, 1.84 x 105 in Crest 
mouthwash, P = 0.0445), Fusobacterium (2.99 x 104 in none, 1.07 x 104 in Crest mouthwash, P = 
< 0.0001), and Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (7.69 x 102 in none, 
1.15 x 102 in Crest mouthwash, P = < 0.0001).  
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Figure 20. Prevalence of species significantly different for Listerine mouthwash and control 
across volunteers. 
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Crest mouthwash also reduced the prevalence of a number of specific species (Fig. 22). 
BuITS detected six species/melts that were significantly lower in Crest mouthwash versus 
control samples. They were BuITS-80.6 (22 in controls, 7 in Crest mouthwash, P = 0.0091), 
BuITS-86.4 (24 in controls, 5 in Crest mouthwash, P = 0.0006), BuITS-87.8 (26 in controls, 11 
in Crest mouthwash, P = 0.0091), BuITS-88 (44 in controls, 22 in Crest mouthwash, P = < 
0.0001), BuITS-88.2 (41 in controls, 23 in Crest mouthwash, P = 0.0012), and BuITS-88.4 (37 in 
controls, 14 in Crest mouthwash, P = < 0.0001). Species Bu10-87.0 was more than two-fold less 
prevalent in Crest mouthwash (58 in none, 18 Crest mouthwash, P = 0.0019). Fusobacterium 
(Fuso-85.0, possibly Fusobacterium periodonticum) was also reduced in prevalence by at least 
two-fold (59 in controls, 26 after Crest mouthwash (P = 0.0014). Fuso-85.2 (possibly 
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Figure 21. Average titers (log) significantly different for Crest mouthwash 
and none across all volunteers. The averages are based on titers from each 
primer per individual in each group. Bu10= bacterial universal primer 16s, 
BuITS= bacterial universal primer ITS, LBITS= Lactobacillaceae, StrepITS= 
Streptococcus, Lachno= Lachnospiraceae/incertae sedis/clostridum 
Iva/Roseburia, and Fuso= Fusobacterium 
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Fusobacterium periodonticum) was reduced by at least 1.6 fold with 59 in controls, 31 in Crest 
mouthwash (P = 0.0069). Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia detected 
species/melts that were significantly lower than the control. Lachno-86.4 (possibly Oribacterium 
sinus), was two- to three-fold lower, 45 in none and 17 in Crest mouthwash (P = 0.0014). 
Lactobacillaceae detected three species/melts with significantly lower titers: LbITS-87.4, 
possibly Abiotrophia defectiva (39 in controls, 9 after Crest mouthwash (P = < 0.0001), LbITS-
87.6 possibly Abiotrophia defectiva, 33 in controls, 19 in Crest mouthwash (P = 0.0134), and 
LbITS-87.8 possibly Abiotrophia defectiva, with 41 in controls, 20 in Crest mouthwash (P = < 
0.0001). 
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Figure 22. Prevalence of species significantly different for Crest mouthwash and control 
across volunteers.  
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3.5.4 Dominant species after Crest toothpaste 
Crest toothpaste reduced average titers by a greater magnitude than the other routines, but 
by at most 4-fold. Four bacterial populations were reduced after the use of Crest toothpaste (Fig. 
23). This included: bacterial 16s (1.30 x 106 in none, 7.21 x 105 in Crest toothpaste, P = 0.0009), 
Lactobacillaceae (1.03 x 104 in none, 4.05 x 103 in Crest toothpaste, P = < 0.0001), 
Fusobacterium (2.99 x 104 in none, 1.64 x 104 in Crest toothpaste, P = 0.0069), and 
Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia (7.69 x 102 in none, 3.53 x 102 in 
Crest toothpaste, P = 0.0138).  
 
 
Significant species were reduced in several targets (Fig. 24). BuITS detected five melt 
temperatures that were significantly lower in Crest toothpaste versus control samples: BuITS-
84.6 (17 in controls, 2 in Crest toothpaste, P = 0.0091), BuITS-86.4 (24 in controls, 8 in Crest 
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Figure 23. Average titers (log) significantly different for Crest toothpaste and none across all 
volunteers. The averages are based on titers from each primer per individual in each group. 
Bu10= bacterial universal primer 16s, LBITS= Lactobacillaceae, Lachno= 
Lachnospiraceae/incertae sedis/clostridum Iva/Roseburia, and Fuso= Fusobacterium 
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toothpaste, P = 0.0047), BuITS-88 (44 in controls, 21 in Crest toothpaste, P = < 0.0001), BuITS-
88.2 (41 in controls, 19 in Crest toothpaste, P = < 0.0001), and BuITS-88.4 (37 in controls, 11 in 
Crest toothpaste, P = < 0.0001). Species Bu10-87.0 was more than two-fold less prevalent in 
Crest toothpaste (58 in none, 20 in Crest toothpaste, P = 0.003). Fusobacterium (Fuso- 85.0, 
possibly Fusobacterium periodonticum) was also reduced in prevalence by at least two-fold (59 
in controls, 30 in Crest toothpaste (P = 0.0051). Fuso-85.2 (possibly Fusobacterium 
periodonticum) was reduced by at least 1.6 fold with 59 in controls, 32 in Crest toothpaste (P = 
0.0094). Lachnospiraceae/ incertae sedis/ clostridum IVa/ Roseburia detected species/melts that 
were significantly lower than the control. The first, Lachno-86.4 (possibly Oribacterium sinus), 
was two- to three-fold lower, 45 in none and 14 in Crest toothpaste (P = 0.0004). 
Lactobacillaceae detected three species/melts with significantly lower titers: LbITS-87.4, 
possibly Abiotrophia defectiva (39 in controls, 20 after Crest toothpaste (P= 0.0004), LbITS-87.6 
possibly Abiotrophia defectiva, 33 in controls, 15 in Crest toothpaste (P= 0.0009), and LbITS-
87.8 possibly Abiotrophia defectiva, with 41 in controls, 14 in Crest toothpaste (P= < 0.0001). 
Streptococcus detected two species/melts that were significantly lower in a few of the nightly 
routines. Strep-87.6 was reduced ~2-fold (73 in controls, 36 after Crest mouthwash, P = 0.01, 
and Strep-88 was reduced more than two-fold (51 in controls, 8 after Crest toothpaste, P = 
0.0027). 
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3.5.5 Dominant species of Colgate toothpaste 
Overall, Colgate toothpaste only reduced average bacterial titers in Lactobacillaceae 
(1.03 x 104 in none, 8.19 x 103 in Colgate toothpaste, P = 0.01; Fig. 25). Titers for each nightly 
routine per branch tested, and all of the figures showing the effects of each nightly routine on 
each volunteer per primer can be found in Appendix J. 
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Figure 24. Prevalence of species significantly different for Crest toothpaste and control 
across volunteers. 
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Significant species were reduced in prevalence, in several target groups (Fig. 26). BuITS 
detected five species/melts that were significantly lower in Colgate toothpaste versus control 
samples. They were BuITS-80.6 (22 in controls, 8 in Colgate toothpaste, P = 0.0168), BuITS-
86.4 (24 in controls, 9 in Colgate toothpaste, P = 0.0091), BuITS-88 (44 in controls, 23 in 
Colgate toothpaste, P = 0.0001), BuITS-88.2 (41 in controls, 17 in Colgate toothpaste, P = < 
0.0001), and BuITS-88.4 (37 in controls, 20 in Colgate toothpaste, P = 0.0024). Species Bu10-
87.0 was more than two-fold less prevalent in Colgate toothpaste (58 in controls, 29 in Colgate 
toothpaste, P = 0.010). Fusobacterium (Fuso- 85.0, possibly Fusobacterium periodonticum) was 
also reduced in prevalence by at least two-fold (59 in controls, 25 in Colgate toothpaste (P = 
0.001). Fuso-85.2 (possibly Fusobacterium periodonticum) was reduced by at least 1.6 fold with 
59 in controls, 36 in Colgate toothpaste (P = 0.0304). Lachnospiraceae/ incertae sedis/ 
clostridum IVa/ Roseburia detected species/melts that were significantly lower than the control. 
The first, Lachno-86.4 (possibly Oribacterium sinus), was two- to three-fold lower, 45 in none 
and 15 in Colgate toothpaste (P = 0.0006).  The second melt/species, Lachno-86.6, was 
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Figure 25. Average titers (log) 
significantly different for 
Colgate toothpaste and none 
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averages are based on titers 
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significantly reduced only after Colgate toothpaste, by ~4-fold (38 in controls, 9 in Colgate 
toothpaste, P = 0.0009). Lactobacillaceae detected three species/melts with significantly lower 
titers: LbITS-87.4, possibly Abiotrophia defectiva (39 in controls, 20 after Colgate toothpaste (P 
= 0.0004), LbITS-87.6 possibly Abiotrophia defectiva, 33 in controls, 15 in Colgate toothpaste 
(P = 0.0009), and LbITS-87.8 possibly Abiotrophia defectiva, with 41 in controls, 17 in Colgate 
toothpaste (P = < 0.0001). Streptococcus detected two species/melts that were significantly lower 
in a few of the nightly routines. Strep-87.6 was reduced ~2-fold (73 in controls, 39 after Colgate 
toothpaste, P = 0.0188). Strep-88 was reduced more than two-fold (51 in controls, 20 after 
Colgate toothpaste, P = 0.0346). 
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Figure 26. Prevalence of species significantly different for Colgate toothpaste and control 
across volunteers. 
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3.5.6 Fold titer decreases of differences in nightly routines 
The above analyses focused on titers averaged over all patients to characterize trends that 
might be expected in general. However, the strongest impacts depended on the individual and 
were muddied by averaging. These widely varying reductions after nightly routines depend on 
the individual, the target, and the treatment are detailed in Appendix L; representative examples 
are shown in Figure 27. For example, five individuals show greater than 10 fold decreases 
Lactobacillaceae after Listerine mouthwash use (Fig. 27A). The volunteers were M01 (↓15.8), 
M06 (↓18.6), M10 (↓17.4), M13 (↓13.6) and M16 (↓10.5). Whereas, Lachnospiraceae/ incertae 
sedis/ clostridum IVa/ Roseburia (Fig. 27B) had four individuals with greater than 10 fold 
decreases after Crest mouthwash use, and of these four, three were different volunteers than seen 
in Lactobacillaceae. The three that were greater than 10 fold were: M02 (↓10.2), M06 (↓43.7), 
M11 (↓17782), M12 (↓55). M06 was seen to be reduced at least 15 fold with both nightly 
routines and targets. 
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A more useful analysis of this information determined the number of volunteers with 
greater than five-fold decreases in titer values (Fig. 28). Both Crest mouthwash and Crest 
toothpaste significantly reduced the populations of Lachnospiraceae/incertae sedis/clostridum 
Iva/Roseburia, in 5 individuals. Listerine mouthwash and Crest toothpaste decreased populations 
of Lactobacillaceae also in 5 individuals. Overall, Colgate toothpaste had the least amount of 
total patients with decreases greater than 5 fold in titers of targets. Whereas, Crest mouthwash 
and Crest toothpaste tied with the greatest number of volunteers with decreases greater than five 
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Figure 27. Average fold decrease in titers. (A) Average fold decrease in titers in Listerine 
mouthwash in Lactobacillaceae, (B) Average fold decrease in titers in Crest mouthwash in 
Lachno= Lachnospiraceae/incertae sedis/clostridum Iva/Roseburia. 
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in target titers. With this knowledge at hand, it would seem that the most effective way to reduce 
all of the target titers tested would be to combine the use of Crest mouthwash and Crest 
toothpaste - where one fails, the other compensates. 
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Figure 28. Prevalence of patients with 5+ average fold in titer difference. Fuso= 
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CHAPTER 4: CONCLUSIONS AND DISCUSSION 
4.1. Overview  
Most of the specific aims originally proposed for this thesis were accomplished. I secured 
an IRB which allowed me to collect saliva samples and patient information from 18 controls and 
18 patients who self-reported xerostomia. I also collected 30 samples from 17 control patients, 
who practiced 5 different nightly oral hygiene routines before donating a saliva sample the next 
morning. I developed a storage buffer that stabilized DNA in these samples for at least 30 days, 
optimized a DNA extraction protocol and showed that it was more efficient at extracting 
amplifiable genomic DNA across almost all tested bacterial species, including Streptococcus 
species that are problematic with commercial extraction kits. I characterized and analyzed 
microbial compositions of these samples using qPCR with broad-spectrum and phylogenetic 
branch specific primers. I established a repository of 364 colony-purified oral bacterial species, 
along with DNA preps of each, and verified 110 of these by sequencing.  
4.2 Key findings  
1. Microbial DNA can be effectively stored in SSB buffer for at least 30 days, and efficiently 
extracted for qPCR with my modified FLB extraction protocol. 
2. Oral bacterial species compositions identified by culture and qPCR were diverse and were 
largely consistent with those characterized by NGS in the literature. 
3. Oral bacterial compositions were dominated by Streptococcus species and those in the 
Veillonella target groups, in both control and xerostomia groups.  
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4. A core group of bacteria seen in all patients included Streptococus, Fungi, Fusobacterium, 
Actinobacteria, Bacteriodaceae/ uc Prevotella and Veillonella. Groups that were seen more 
sporadically included Lactobacilliaceae, Lachnospiraceae, and Betaproteobacteria. Patients 
typically had at least 3 species at co-dominant titers, and these changed daily, often by an 
order of magnitude. 
5. Surprisingly, total bacterial titers and overall compositions at the branch levels were not 
dramatically different in control versus xerostomia groups. 
6. However, several subgroups of bacteria (Lachnospiraceae and Bacteroidaceae) were reduced 
by 5 to 20 fold on average among xerostomic patients. 
7. However, there were many bacterial and fungal species that were more prevalent in patients 
with low saliva flow than those with high flow, and others bacterial species that were more 
prevalent in high flow. These differences were enhanced by considering only patients whose 
xerostomia was induced by medication. 
8. Nightly oral routines did have an impact by reducing next-morning saliva bacterial 
compositions and titers, but this was highly variable between individuals and routines. 
Overall, Crest toothpaste and mouthwash routines reduced titers more in more individuals. 
4.3 SSB/FLB as storage/lysis buffer 
Microbial DNA can be effectively stored in SSB buffer for at least 30 days, and 
efficiently extracted for qPCR with my modified FLB extraction protocol. With all of the 
previous experiments on buffer/lysis saliva storage and extraction efficiency, it was in the 
study’s best interest to use the saliva storage buffer SSB with lysis of FLB. The SSB has been 
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optimized for the saliva samples in this study, finding that a 4.0 mL kills cells in the saliva and 
prevents nucleic acid degradation for at least 30 days at room temperature.  We also optimized 
sample DNA extraction, finding that microbes pelleted from the storage solution, then subjected 
to hot detergent–lysis, is as good or better across phyla than commercial DNA extraction kits. 
4.4 Culture cell library 
Oral bacterial species compositions identified by culture and qPCR were diverse and 
were largely consistent with those characterized by NGS in the literature. Of my 110 sequenced 
cultures I found 33 different species from 8 different Families. I was able to culture 3 of the 6 
major phyla from HOMD (Firmicute, Actinobacteria, and Proteobacteria) 3. All of my cultures 
were not identified by sequencing, because of lack of funds. Therefore, I cannot compare 
distinctions between xerostomia individuals and control saliva cultures. Also, I did not culture 
saliva on media that supported fungi growth and in-turn I cannot come to any conclusions on the 
fungal populations in my culture library. However, my selective sequencing did identify species 
consistent with the literature on oral microbiota, including: Lactobacilli spp. 17, 25, Neisseria, 
Rothia, Gemella 28, Streptococcus, Neisseria, and unclassified bacteria (Uncl) 2. This validates 
the quality and analysis of my sequencing data. With further sequencing of the entirety of my 
library, I am confident that we would be able to either confirm or refute the culture differences in 
xerostomia or healthy individuals. 
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4.5 Xerostomia vs. Control Arm 
Saliva flow tests showed significant reductions in averages of unstimulated flow, 
stimulated flow and saliva flows sum in self-reported xerostomia versus controls. However, there 
was a great deal of overlap between these two groups. This could be due to poor categorization 
based on ambiguous symptoms and self-reporting, in the first place. Individuals in the control 
group that matched volumes of those in the self-reported xerostomia group could have never 
noticed that they actually have low spit flow. In this case there could have been poor tools to put 
each individual in each group. There was no significant difference in the pH of these two groups.  
Surprisingly, bacterial titers and overall compositions at the branch levels were not 
significantly different in control versus xerostomic groups. Oral bacterial compositions were 
dominated by Streptococcus species and those in the Veillonella target groups, in both control 
and xerostomia groups. These saliva compositions were also found to be part of the major core 
genera in healthy oral saliva in literature 2. Literature also stated that Streptococcus was the most 
abundant groups that dominated nearly all of the oral mucosal sites 4, this was also found true in 
my volunteers’ saliva. Streptococus and Veillonella 28 were also prevalent in Xerostomia 
patients. A core group of bacteria seen in all patients included Streptococus, Fungi, 
Fusobacterium, Actinobacteria, Bacteriodaceae/ uc Prevotella and Veillonella. Patients typically 
had at least 3 species at co-dominant titers, and these changed daily. 
Comparing target levels with-in the groups revealed that there was an 18 fold reduction in 
Bacteroidaceae and a 5 fold reduction in Lachnospiraceae average titers in xerostomia. In fact, 
all other significant differences between the two groups (less than 5 fold difference) showed a 
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reduction in xerostomia. A logical explanation for this could be from the amount of saliva tested, 
xerostomia patients could have had a harder time getting saliva into the test tubes causing this 
“reduction” of cells. This also held true when comparing high flow to low flow and “medication-
induced xerostomia” (MIX) to controls. 
However, there were many specific bacterial and fungal species that were more prevalent 
in xerostomia patients than controls, and other bacterial species that were more prevalent in 
controls. Xerostomia patients were found to have a higher prevalence in species OidesITS-81.6, 
LBITS-90.2, BProITS-84, Fungi-84.4, Fungi-84.8, and Fungi-86.6. Some of these differences 
were enhanced when comparing groups of low flow to high flow, such as Fungi-84.4, Fungi-
84.8, Fungi-86.6, LBITS-90.2. There were also higher prevalence seen when comparing MIX to 
controls in: BuITS-81.2, Fungi-86.4, BProITS-84.0, and LBITS-87.6. BuITS-84.6, LBITS-84.6 
were only seen in MIX. These species being higher in prevalence or found only in our dry mouth 
patients could explain their negative oral hygiene. Fungi, for instance was found to be involved 
with oral mucosal disorders 15 and Lactobacillus has been found to be associated with dental 
caries 9. The species OidesITS-88.6 was non-existent in any of the low flow patients, and 
BProITS-85.6 and OidesITS-90.0 were non-existent in the MIX patients. These species that are 
lacking in the dry mouth patients could be the bacterial that is stabilizing the healthy oral 
microbiome. Such as, Bacteriodetes have been abundant in healthy oral saliva 2. Identification of 
these species through sequencing can give us a better understanding of their role.  
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4.6 Nightly Oral Hygiene Practice Arm 
Nightly oral routines did have an impact by reducing next-morning saliva bacterial 
compositions and titers, but this was highly variable between individuals and routines. Average 
titers across all individuals and Lactobacilli and Fusobacterium targets titers were significantly 
reduced after Listerine mouthwash. Across all species showing differences, Listerine mouthwash 
was found to reduce prevalence. All average target titers and species after nightly use of Crest 
mouthwash was significantly reduced. The nightly use of Crest toothpaste showed 4-fold 
decreases in average titers of bacteria 16s, Lactobacilli, Lachnospiraceae, and Fusobacterium, as 
well as decreases in significant species. Colgate toothpaste resulted in significant decrease in 
Lactobacilli and was also significantly reduced in several species prevalence. The use of these 
nightly routines were found to significantly reduce average titers and certain species, as 
expected.  
However, individually volunteers had widely varying reductions in bacterial titer 
populations following a specific nightly routine. In most cases only few volunteers had greater 
than 5-fold decreases in bacterial titers after use of a nightly routine. Across all the targets tested 
and nightly routines tested, there were only 6 instances in which Colgate toothpaste reduced 
titers by more than 5-fold, only 11 times after Listerine mouthwash.  Crest mouthwash and 
toothpaste reduced titers more often, 14 occurrences each. Overall, Crest toothpaste and 
mouthwash routines reduced titers more in more individuals. The groups affected most varied 
between the two, suggesting that a combination of both treatments might be synergistic. 
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4.7. Study Limitations 
1. Only saliva samples were taken, restricted by feasibility, so bacterial compositions in other 
oral niches, such as embedded in subgingival plaque, or tongue, were not collected and 
therefore might be more of a factor in xerostomia or in assessing nightly routines. 
2. Data from the xerostomia versus control patients’ needs more analysis at the individual level 
to supplement my analysis of averaged data. 
3. Amplicons that were identified by melting temperatures as being more prevalent in one 
group or after a nightly routine, need to be identified to species by sequencing. 
4. A number (155) of species that are potentially not in public databases were found by 
sequencing but need further analysis to confirm whether they truly represent novel species. 
5. Funding restricted use of NGS. 
4.8. Future studies  
In addition to conducting experiments to address the limitations listed in Section 4.7, if I had 
another 6 months, these are the experiments I would pursue.  
In the xerostomia arm, I would address the potential role of species that were more prevalent 
in patients with low saliva flow. Since total bacterial loads were not dramatically different, the 
poor oral hygiene status of the group (e.g. twice the incidence of cavities) may result from 
virulence traits of these species, such as elaboration of metalloproteinases or enhanced biofilm. 
Therefore, I would perform in vitro assays of relevant phenotypes, on pure cultures of species I 
identified in this study to be more prevalent in xerostomic samples. 
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In the oral hygiene arm, I would pursue the observation that specific individuals show 
much more dramatic reductions to a nightly oral routine than others. My hypothesis would be 
that this variation results from specific differences in starting bacterial compositions, at the 
species or even strain level. This effort would be enhanced by NGS analysis, which I could 
perform on pooled and barcoded DNA samples in my repository. I would also test whether pure 
cultures of species unique to high-responding patients were more sensitive to the mouthwashes 
or toothpastes than their cousins from non-responding patients, with standard microbroth dilution 
and viability assays. 
The highly individualized responses shown after specific nightly hygiene practices 
suggest that a large-scale prospective study is warranted. Participants’ responses to each routine 
would be characterized as I did, and then they would be assigned their optimal hygiene regimen, 
and tracked long-term with monthly sample monitoring. The issue I’d focus on, is whether 
consistent reduction in one or more specific bacterial groups, which would differ in each cluster 
of patients is strongly correlated with better oral hygiene. This I would quantify at the dentist, 
with cavity and gum health assays. I’d also include a comparison group that was randomized 
with respect to which nightly routine caused the largest reductions, to determine if 
individualized, non-random routine groups had better oral health outcomes. 
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APPENDIX A: QUESTIONNAIRE 
Code ID:______ Date:_______ 
Dental health questionnaire 
Age:_______ Sex:_______ Race:________ Ethnicity:__________ 
Have you read and signed the informed consent form for this study?  YES ___ NO___ 
1. Are you currently in any pain? YES ___ NO___ Describe if yes_______________________________ 
2. Have you been hospitalized in the last two years? YES ___ NO___ Reason if  
yes_________________________ 
3. Have you seen any physicians in the last two years? YES ___ NO___ Reason if  
yes_______________________________ 
4. Have you been taking any medication in the past two years: YES ___ NO___ Describe if  
yes_______________________ 
5. Are you allergic to anything? YES ___ NO___ Describe if yes_______________________________  
6. Circle any condition you have had, or box if you currently have it:  
 
 
 
 
 
 
 
 
7. How often do you brush? Once daily  ____ Twice daily ____ Three times daily___ Other____ 
8. What brand of toothpaste do you currently use?______________________ 
9. Your brush is: Soft ___ Medium ___ Hard___  
10. Your brush is: Manual____ Electric____ Brand_______________________ 
11. How often do you floss? Once daily  ____ Twice daily ____ Three times daily___ Other____ 
12. How often do you use a fluoride mouthwash? Once daily  ____ Twice daily ____ Three times  
daily___ Other____  Brand________________ 
13. How often do you see your dentist? Once a year____ Twice a year____ Other_____ 
14. When you visit your dentist, do you most often have: 
a. No new cavities___ b. One new cavity___ 
c. Two new cavities___ d. Other___ 
15. How many total cavities have you had filled? _____ 
16. How many root canals have you had?______ 
17. How many crowns have you had?______ 
18. Do you wear dentures? YES____NO____ If yes, for how long have you had 
them?_________________ 
19. Have you ever been treated for periodontal/gum disease? YES ___ NO___ Most recent date:______  
20. Have you had cosmetic dentistry, such as caps or veneers? YES____ NO____  List_______ 
21. Would you say your mouth is: comfortable?_____ moderately uncomfortable_____ very  
uncomfortable____ if so, describe:____________________________________________ 
22. Do you have or have you ever had any of the following, if so, what was the most recent incident:  
ms? YES ___   NO____   When?_____ 
 
AIDS/HIV Asthma Radiation treatment 
Heart Disease/Failure  Cold Sores Chemotherapy 
Liver Disease High blood pressure Shortness of breath 
Heart Attack Seasonal allergies Kidney problems 
Hepatitis A, B, or C Epilepsy/seizures Psychiatric care 
Diabetes Sinus problems 
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 Sensitivity to sweets? YES ___   NO____   When?_____  
 
 
 
YES ___   NO____   When?_____ 
 
 
 
 
h biting cheeks/lips?  YES ___   NO____   When?_____ 
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APPENDIX B: MEDIA 
Media Name 
Media 
Type Media Full Name Ingredients 
Blood TSA Agar 
Trypticase Soy Agar + human 
blood 
30 g TSA powder, 15 g agar powder, 1 L 
deionized water, 50 mL human blood 
MLT Max Agar Mes-Lib-Thio-Casein-Starch  
15 g Proteose Peptone No3, 4 g MES 
powder, 5 g Glucose, 5 g yeast extract, 5 g 
NaCl, 5 g Casein enzymatic hydrolysate, 1 g 
starch, 0.5 g Cysteine HCL, 1.25 mL 
Thioglycollate, 1 L deionized water 
Rogosa Agar Agar Rogosa Agar 
660 mL deionized water, 15 g Agar, 330 mL 
Rogosa stock 
TSA Agar Trypticase Soy Agar 
30 g TSA powder, 15 g agar powder, 1 L 
deionized water 
YPD + AMP Agar 
Yeast extract/ Peptone/ 
Dextrose Agar 
 10 g Peptone, 5 g yeast extract, 20 g 
dextrose, 15 g Agar, 1 L deionized water, 
1ml of a 10 mg/mL stock of  Ampicillin 
added after autoclaving 
LIB + 
Supplements Broth 
Lactobacillus iners 
Broth+Supplements (modified 
from ATCC medium 1685 
NYC III) 
0.5 g/L cysteine, 4 g HEPES, 15 g Proteose 
Peptone No.3 (BD 211693), 5 g NaCl, 875 
mL deionized water, 5 g Glucose, 25 mL 
Fresh Yeast Extract (Gibco 360-8180), 100 
mL Heat inactivated horse serum 
MYEG Broth Milk/Yeast Extract/Glycerol 
130 g dried milk, 5 g yeast extract, 10 g 
dextrose, 1 L deionized water, autoclave and 
cool to add 150 mL 100%  sterile glycerol 
FLBA Buffer Fungal Lysis Buffer-A 
8 mL deionized water, 2 mL 10% 
TritonX114, 20 μL 0.5 M EDTA 
FLBB Buffer Fungal Lysis Buffer-B 
2.5 mL 2 M Tris pH 8.3, 0.2 mL 0.5 M 
EDTA, 0.41 mL conc. HCL, 22 mL 
deionized water 
1 x PBS Buffer 1 x Phosphate Buffered Saline 
 8 g 137 mM NaCl, 0.2 g 2.7 mM KCl, 1.44 
g 10 mM Na2PO4, 0.24 g 1.8 mM KH2PO4 
(Cold Spring Harbor Laboratory Press, NY) 
1 x SB Buffer Buffer 1 x Sodium Boric acid Buffer 
~3700 ml deionized H2O (genetic), 100 mL 
40 x SB, 80 uL Ethidium Bromide 52, Check 
pH to be ~8.0, make as 40X stock 
SSB Buffer Saliva Storage Buffer 
800 mL deionized water, 5.88 g sodium 
citrate, 700 g ammonium sulfate, 40 mL 0.5 
M EDTA, adjust pH to 5.2 with sulfuric acid 
1 x TE Buffer 1 x TE 10 mM 83 Tris, 1 mM EDTA 
101 
 
2% Agarose 
LE Gel Gel 2% Agarose LE Gel 
250 mL deionized water, 5 g Agarose LE 
Powder, 6.25 mL 40 x SB Buffer, 5 uL 
Ethidium Bromide 
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APPENDIX C: ORAL CELL LIBRARY 
Table can be found in: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs  
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APPENDIX D: QPCR PRIMERS 
Table can be found: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs  
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APPENDIX E: SEQUENCING MATCHES 
Table can be found: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs  
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APPENDIX F: QUESTIONNAIRE FOR XEROSTOMIA AND CONTROL PATIENTS 
Table can be found: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs  
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APPENDIX G: XC TITERS 
Please see: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs  
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APPENDIX H: XC DOMINANT SPECIES 
Please see: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs  
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APPENDIX I: QUESTIONNAIRE FOR NIGHTLY ROUTINE VOLUNTEERS 
Please see: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs  
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APPENDIX J: NIGHTLY ORAL ROUTINE TITERS 
Please see: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs  
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APPENDIX K: NIGHTLY ORAL ROUTINE DOMINANT SPECIES 
Please see: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs 
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APPENDIX L: REDUCTION BY NIGHTLY ROUTINE PER INDIVIDUAL 
Please see: 
https://drive.google.com/drive/folders/0BwlH15OQpZ4kfjVPV3RxSzd4VkNJSDN1TnFVZjhFa
WY1d2pnUFdmdUd5czVTQ2g0XzVRaWs 
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A thesis presented on the characterization of oral microbiota in xerostomic versus non-
xerostomic volunteers and in daily samples following standard oral hygiene practices. 
Xerostomia is a difficult and burdensome disease that can be very difficult to diagnose. 
Understanding the oral microbiota between these diseased and healthy (non-xerostomic) can give 
us great insight on new treatments and/or prevention. Goals of the study included determining 
whether there substantial differences in oral microbial populations between the two groups, and 
whether varying nightly oral hygiene practices had an impact on next-morning oral microbiota 
titers or composition. Microbial loads were determined by qPCR using broad-spectrum primers. 
Microbial compositions were estimated based on melt curve analysis of amplicons that spanned 
the internal transcribed spacer between small and large ribosomal RNA genes, and by qPCR 
using phylogenetic branch-specific primers. The project succeeded in developing and optimizing 
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a storage media that allowed 30 day room temperature storage, and an DNA extraction method 
that outperformed commercial kits. 
The xerostomia versus control study used three sequential daily saliva samples, collected 
from 18 xerostomia and from 18 healthy, control volunteers. Fungal populations and several 
potentially novel species were found to be more significantly prevalent in xerostomia patients as 
compared to healthy (P = 0.001). Surprisingly, total bacterial titers and overall compositions at 
the branch levels were not dramatically different in control versus xerostomia groups. 6. 
However, several subgroups of bacteria (Lachnospiraceae and Bacteroidaceae) were reduced by 
5 to 20 fold on average, and specific species were less prevalent; among xerostomic patients, and 
none were elevated. These studies suggest fungal species may play a role in the poorer oral 
hygiene of xerostomic patients and that more detailed analysis using next generation sequencing 
is warranted. 
Mouthwashes and toothpastes are composed of several different ingredients, many of 
which purported to have anti-caries or anti-gingivitis activities. However, the quantitative impact 
of these is not well studied. The objective to this part of the thesis was to examine the shift in 
populations after a specific oral hygiene practice repeated over 5 nights and assayed from saliva 
the next mornings. This essentially uses the mouth as in incubator for microbial regrowth. A total 
of 30 saliva samples were collected from 17 individuals the morning after a given nightly oral 
hygiene practice, including no routine, Listerine mouthwash only, Crest mouthwash only, Crest 
toothpaste only, and Colgate toothpaste only. These samples were analyzed using qPCR and 
sequencing. Total bacterial loads returned to approximately the same levels after the 4 routines 
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compared to no routine. Overall, Crest toothpaste and mouthwash routines reduced titers more in 
more individuals. However, individual routines did have an impact by reducing next-morning 
saliva bacterial compositions and titers of specific groups, but these reductions were highly 
specific to the individual and the routine. This suggests that we have highly individualized 
responses to common oral hygiene products, and that tailoring our choice of these to optimize 
specific bacterial group reductions could improve oral health. 
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